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The c-Jun N-terminal kinases (JNKs) are MAPK family members and
are activated by stress, growth factors and cytokines. They are encoded by
three separate genes (jnk 1, 2, and 3), spliced alternately creating 10 isoforms.
JNK signaling promotes both cell death and cell survival in a stimuli and
tissue specific manner and is also implicated in tumorigenesis. Using the Poly-
oma Virus Middle T Antigen (PyVMT) transgenic mouse model where jnk2
was either expressed or deleted, we found that the PyVMTjnk2-/- tumors ex-
pressed higher Epidermal Growth Factor Receptor Substrate 8 (EPS8) mRNA
and protein. EPS8 regulates EGFR signaling from Ras to Rac and EGFR
trafficking via Rab5 and RN-Tre. EPS8 is a prime candidate for connecting
the EGFR signaling to actin cytoskeleton remodeling, thus mediating cell mi-
gration, a critical step in metastasis. In migration assays, PyVMTjnk2+/+
cells migrated five fold more than the PyVMTjnk2-/- cells. Re-expression
of JNK2α in the PyVMTjnk2-/- cells rescued this phenotype. Expression of
vi
shRNA EPS8 in the PyVMTjnk2-/- cell increased migration in vitro. EPS8
localization at dorsal ruffles and internalization of EGF-EGFR complexes co-
incided with JNK2 expression. Expression of shEPS8 in the PyVMTjnk2-/-
cells increased EGF internalization suggesting that in absence of JNK2, EPS8
participates in Rab5-RN-Tre complex that inhibits EGFR internalization. Fi-
nally, we report that in absence of JNK2, EPS8 protein stability is greatly
increased, suggesting that JNK2 is essential for endosomal sorting and degra-
dation of EGFR associated cargo, of which EPS8 is a critical part. In contrast,
silencing JNK1 (p46) in 4T1.2 mammary tumor cells, consistently enhanced
cell invasion and tumor growth. Tumors derived from orthotopic injection of
the 4T1.2shJNK1 expressing cells into the mammary fat pad reached target
volume significantly earlier than non-silencing vector expressing tumors. When
injected intravenously, significantly higher lung metastasis was observed in the
4T1.2shJNK1 group. The more aggressive behavior of 4T1.2shJNK1 tumors
was associated with an increase in CCR5 and pAkt as detected by microar-
ray analysis. Taken together, our data suggest that JNK1 suppresses the
expression of proteins associated with tumor growth and invasive phenotype,
contributing to tumor progression.
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Chapter 1
Introduction
1.1 The Hallmarks of Breast Cancer
1.1.1 The Disease
Cancer is a disease involving dynamic changes in the genome.
—Weinberg, 2000
The incidence of cancer arose with the emergence of complex life forms,
almost as a natural consequence of evolution. Metaphorically, the dynamics of
evolution are in full throttle within the tumor microenvironment itself, echoing
Robert Weinberg’s comment. The earliest description of the human disease
dates back to 3000 B.C Egypt, although the term ‘carcinoma’ was proposed
by Greek physician Hippocrates several centuries later.
Globally, breast cancer is the most common cancer amongst women
with an estimated 178,480 new cases of invasive breast cancer and 62,030 ad-
ditional cases of ductal carcinoma in situ (DCIS) in 2007 (American Cancer
Society). The expected number of deaths from breast cancer in 2007 is pre-
dicted to be about 40,910 in the US and over 500,000 worldwide. In the US,
1 in 8 (12.500%) women will develop invasive breast cancer, 3% of whom will
not survive the disease (American Cancer Society, Statistics 2009).
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My dissertation addresses breast cancer, specifically the various factors
involved in metastasis of breast cancer cells. Cancer starts as a tissue specific
disease. To understand cancer one has to first understand the normal tissue.
I will briefly address the biology of mammary gland since normal tissue devel-
opment provides us with insight into the various ways by which cell growth
goes awry [3].
The Biology of the Mammary Gland
The mammary gland is an evolutionary milestone: the defining feature
of an entire ’Class’. There is a developmental hierarchy within the mammary
gland beginning at the time of embryogenesis and continuing well through the
adult life. Dramatic changes occur during puberty and pregnancy leading to
functional development and differentiation. In both mice and humans, puber-
tal and adult stages are regulated by hormones. The embryonic mammary
structure develops through sequential and reciprocal cross-talk between the
epithelium and the mesenchyme. The basic steps in murine pubertal mam-
mary development include Terminal End Bud (TEB) development and inva-
sion of the fat pad accompanied by ductal branching. Hormones associated
with pregnancy induce cellular proliferation, alveolar development for milk
storage and subsequent lactation. During involution (after weaning), alveoli
regress via apoptosis, and the gland remodels to its original pre-pregnancy
state. The gland is regenerated during subsequent pregnancies from pluripo-
tent precursors. Mammary stem cells are critical for maintaining the structure
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of the gland throughout development [83]. The functional milk-producing unit
in the mammary gland, the alveolus, is composed of luminal (secretory) and
basal (myoepithelial) cells, which are descendants of a common progenitor cell
[81].
Breast cancers are usually derived from the epithelial cells lining the
ductal unit [81]. Many of the signaling pathways ascribed to mammary de-
velopment are activated or deregulated in breast cancer [193]. Thus, a better
understanding of the roles of these pathways in normal development will be of
great importance in understanding the disease progression. For example, the
involuting mammary gland is characterized by an inflammatory/wound heal-
ing signature with high matrix metalloproteinase activity, collagen deposition
and release of fibronectin and laminin. These effects are also associated with
tumor progression. Based on the structural and functional similarity of the
mouse and human mammary gland, the mouse has emerged as a primary ani-
mal model for human breast cancer [194]. Transgenic mice can be manipulated
to develop hyperplasias and tumors that are histologically and pathologically
comparable to lesions in humans.
Risk Factors for Breast Cancer
Familial factors including mutations in several genes such as BRCA1
(Breast Cancer1), BRCA2 (Breast Cancer2), P53 and PTEN (Phosphatase
and tensin homolog) clinically increase the risk of developing breast cancer.
Risk also increases with age in both men and women. Reproductive history
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such as increased lifelong exposure to female reproductive hormone like estro-
gen increases risk [15]. Immediately after child birth there is a short window
of increased risk due to rapid cellular proliferation prior to terminal differ-
entiation preceding lactation [22]. Hormone replacement therapy along with
dietary and lifestyle factors, such as obesity, diabetes, alcohol consumption,
and smoking, increase the risk of breast cancer. Finally, exposure to ionizing
radiation due to nuclear explosion or medical diagnostics increases a person’s
chances of developing breast cancer [43].
Pathological Classification of Tumor Types
World Health Organization’s classification of breast tumor is based on
histopathology and hematoxylin/eosin staining and classifies breast carcinoma.
The two major categories of breast carcinoma are:
• Ductal ( 85% of cases)
• Lobular (15% cases)
These groups are further subdivided as non-invasive (in situ) or invasive (infil-
trating). Carcinoma in situ is defined as the presence of proliferative malignant
epithelial cells in the ductal and lobular acini are noninvasive at diagnosis and
confined by the basement membrane. Ductal carcinoma in situ (DCIS) is a
subtype where malignant cells are located intraductally as opposed to lobular
carcinoma in situ (LCIS). Notably, only DCIS can be detected in mammo-
grams.
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Invasive ductal carcinoma accounts for 65-80% of all breast malignan-
cies and is commonly designated by a modifier NOS (not otherwise speci-
fied) to distinguish it from special morphological subtypes which have slightly
better prognosis. Pathological features used for clinical prognosis include tu-
mor size, presence of axillary lymph node, grade (differentiation grade: well-
intermediate-poor) and lymphatic vascular invasion.
Invasive lobular carcinoma (5-10% of all invasive carcinomas) is char-
acterized by invasion of small, monotypic mammary carcinoma cells into the
stroma in linear strands. Mutation in E-cadherin is strongly correlated with
this disease.
Other subtypes include mucinous (colloid) carcinoma, medullary carci-
noma, papillary carcinoma, tubular carcinoma, and inflammatory carcinoma.
Together they comprise 9% of all invasive carcinomas [43].
Staging of Breast Cancer (Based on American Joint Committee on
Cancer- AJCC)
The AJCC staging system includes both clinical and pathological stag-
ing based on T- tumor, N-nodes and M- metastasis characteristics. One draw-
back of this system is that it does not take the metastatic growth rate into
account. According to this system a patient with a long history of relatively
slow indolent disease will have the same grade as one who reached a similar
state with a very aggressively growing tumor in a much shorter time span [43].
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Prognostic and Predictive Factors
Prognostic factors are measurements taken at the time of surgery or
diagnosis that are related to the survival, disease free survival or local con-
trol of the disease in the patient. Predictive factors extrapolate the degree
of response to a particular line of treatment. These factors include, estro-
gen and progesterone receptor expression status, HER2/NEU expression, or
amplification, lymphovascular invasion, proliferation index, plasminogen acti-
vator system status and additional molecular genomic factors such as patient
specific gene expression signatures [43].
Treatment and Therapeutics
The surgical approach is the most conventional course of treatment
for most DCIS cases. Post mastectomy radiation treatment is prescribed to
reduce the risk of local-regional recurrence and to increase overall survival.
Lumpectomy, on the other hand, is usually followed by irradiation to reduce
risks of ipsilateral breast cancer recurrence.
Adjuvant systemic therapy is used to eliminate occult tumor cells or
metastasis and includes systemic hormone treatment, chemotherapy or both.
tamoxifen, a classic Selective Estrogen Receptor Modulator (SERM), is the
drug of choice for hormone receptor positive breast cancer patients. Typi-
cally tamoxifen treatment for 5 years in ER/PR +ve patients reduces risk of
recurrence. In premenopausal women, treatment ranges from tamoxifen, ovar-
ian ablation, leutenizing hormone releasing agonists (Goserelin), overectomy,
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ovarian irradiation, or progestins like medroxyprogesterone acetate (Provera).
In postmenopausal women, aromatase inhibitors such as anatrozole along with
SERMs, progestins, and high dose estrogen have shown therapeutic success.
Chemotherapy drugs commonly used in breast cancer treatment in-
clude anthracycline (Doxorubicin), taxanes (Paclitaxel), Cyclophosphamide,
methotrexate and 5-fluorouracil. To treat HER2+ve patients, trastuzumab
(Herceptin), a humanized monoclonal antibody directed against the extracel-
lular domain of HER2 is used clinically [43].
1.2 Metastasis—The Last Frontier
1.2.1 Dissecting the Metastasis Cascade
Advances in screening, surgery, radiation, chemotherapy, or endocrine
therapy have increased the survival rate of patients with early stage disease.
However, the 18- 24 month median survival period for patients with metastases
remains unchanged.
The predominant cause of death in patients with breast cancer is metas-
tasis of the primary tumor into distant organs. This fatal progression of solid
malignancies is a complex, multistep process whereby transformed cancer cells
from the primary tumor spread to distant organs via sequential steps. These
steps include local invasion, intravasation,(invasion of cancer cells through
basement membrane into the systemic circulation), survival during transporta-
tion, extravasation (exit from blood vessels), and finally establishment of mi-
crometastases at new sites of colonization 1.1. Even though the primary tumor
7
Figure 1.1: The Metastasis Cascade.
Disseminated cells from the primary tumor proteolytically degrade the ECM and
BM,and intravasate into the lymph nodes . Circulating tumor cells either remain dormant
or reach distant sites, where they extravasate out of the lymphatic system, colonize in the
new site and proliferate to form secondary tumors (Adapted from Klaus Pantel and Rudd
Brakenhoff, Nature Reviews of Cancer, 2004).
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is often responsive to radiation and chemotherapy, the new metastatic colonies
are far more aggressive and virtually untreatable, leading to the poor progno-
sis.
The word ‘metastasis’ was coined by the French gynecologist Recamier
in 1839 to describe the invasion of the bloodstream by cancer cells. It has been
debated for decades how cancer cells acquire metastatic capability. Whether
metastases are derived from distinct subpopulations of tumor cells within the
primary site with higher metastatic potential, or they originate from a ran-
dom fraction of tumor cells, is still an ongoing debate. Earlier gene expression
studies have shown that the metastatic subset of tumor cells are not clonal
but rather are inherent features of the tissue [234]. Until recently, metastasis
was clinically detectable in patients only at an advanced stage of the disease,
leading to the dogma that metastasis is a non random and selective process
occurring during the later stages of tumor progression [234]. However, when
tumor cell lines cultured in vitro were transplanted into the mice, a small sub-
population of cells from the primary site could escape, survive and proliferate
implying that the genetic signature of a subset of cells changes rather early
and provides a selective advantage in metastasis. This subpopulation concept
by Fidler’s group is widely accepted [59], but an exclusive explanation to “The
Progression Puzzle”. Bernard and Weinberg have argued that the metastatic
process is a stochastic event, giving all primary tumor cells equal metastatic
potential [243] [13]. This concept of plasticity of primary tumor cells was sup-
ported by evidence that shows metastasis to be an early ‘byproduct’ of the
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embryonic process of epithelial mesenchymal transition (EMT) [243] whereby
epithelial tumor cells undergo dramatic genetic changes to gain mesenchymal
traits, in response to signaling cues from other tumor cells or the surrounding
stroma. The mesenchymal phenotype facilitates dissemination and metasta-
sis, as indicated by a tight association of mesenchymal-related gene expression
with aggressive breast cancer subtypes [243]. EMT endows normal and trans-
formed mammary epithelial cells with stem cell like properties, including the
ability to self-renew and efficiently generate tumors. Thus, breast cancer stem
cells which comprise of stem cells, are resistant to many conventional cancer
therapies and may promote tumor relapse [243].
Various oncogenes, tumor suppressor genes and metastasis suppressor
genes modulate invasiveness and the metastatic potential of tumor cells. Ge-
nomic instability during the various cycles of normal mammary gland devel-
opment can alter signaling pathways leading to transformation of normal cells
into invasive cancer cells [157]. Changes in growth factor signaling, cell-cell
adhesion, gene expression, cell motility or shape are often associated with such
altered gene expression.
Current research is directed towards understanding the rate limiting
steps in tumor genetic and epigenetic changes, along with the role of non-
malignant cells in the tumor microenvironment. For example, myeloid pro-
genitor cells of the distant bone marrow are recruited by breast cancer cells to
enhance their survival, growth, invasion and dissemination [62]. Overall, the
paracrine factors of the tumor microenvironment, the immune surveillance sys-
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tem, and angiogenesis are all conspirators in the propagation of the metastatic
cascade.
1.2.2 Tumor-Microenvironment-Key Determinant of Metastatic Po-
tential and Site of Metastasis
Tumors cells and their modified microenvironment constitute an un-
organized tissue with a variety of host cell types that communicate with the
genetically unstable cancer cells. Tumor micro-environment provides stromal
fibroblasts and infiltrating immune cells to the tumor to aid their malignant
progression. The extracellular matrix along with blood and lymphatic vas-
culature are part of the supporting cast. Together with the ‘co-opted’ nor-
mal cells, the surrounding stroma provide structural support, growth factors,
chemokines, and matrix degrading enzymes that facilitate tumor proliferation
and invasion. Additionally, such altered stromal environment also hinders
effective drug delivery [107], [22].
The microenvironment consists of extracellular matrix (ECM), a cohe-
sive, three dimensional macromolecular infrastructure composed of collagens,
laminins, fibronectin and heparan sulfate proteoglycans that maintain cell-cell
tight junctions and cell matrix adhesions [15]. The basement membrane (BM),
a more specialized part of ECM, physically separates the epithelial tumor cells
from the stroma and its endothelial components. In tumors, the ECM is re-
modeled by matrix metalloproteinases (MMPs). ECM degradation facilitates
angiogenesis induced by the primary tumor and dissemination of tumor cells
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into the vasculature [22] .
The specific microenvironment of the organ where the metastasized
cells colonize, modulates their topography. It is perplexing how tumors cells
of a given tissue are predisposed to invade specific organs, for example, breast
cancer cells preferentially metastasize to the bone and the lung.
A process akin to leukocyte ‘homing’ has been observed in malignant
progression of breast tumors [120]. Gene expression studies showed that pri-
mary breast cancer cells express high levels of chemokine receptors CCR7 and
CXCR4. Their respective ligands CXCL12 and CCL21 are expressed by lung
and regional lymph [142].This suggests a role for these chemokines as a ’hom-
ing device’ for metastases. When CXCL12/ CXCR4 interactions were inhib-
ited, lung metastases were significantly reduced [142], [156]. One inflammatory
chemokine of the Interleukin-8 superfamily, called RANTES(Regulated on Ac-
tivation, Normal T Expressed and Secreted)or CCL5, attracts monocytes from
the systemic circulation and modifies T-cells activity. CCL5 is strongly im-
plicated in invasive breast cancer progression [141]. In biopsies of 61 patients
with advanced stages of breast carcinoma, 74% had increased CCL5 levels
while only 15% of 26 women with benign disease had comparably high lev-
els of CCL5 [141]. In addition to breast cancer, high levels of CCL5 were
reported in melanoma, lung, prostrate and pancreatic cancers [224]. It is be-
lieved that CCL5 induces mammary tumorigenesis by inducing angiogenesis
and increasing vascularity [213].
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1.2.3 Tumor Cell Motility
Cell migration is a critical step for invasive phenotype and hence can
be utilized to develop new therapeutic targets [31], [241]. Structures like pseu-
dopodial extension, and membrane ruffling are detectably higher in tumor cell
compared to normal counterparts [103].Cancer cells migrate as single cells or
in small groups to spread from the initial site of tumor growth [190]. Host
derived growth factors as well as secreted factors from the tumor function as
autocrine signals to promote motility [41]. Acquisition of the invasive pheno-
type is characterized by both the loss of cell-cell interactions and increased
cell motility [41]. Motile cancer cells are able to enter the blood or lymph
vessels (intravasation). These cells cross the vessel wall to exit the vasculature
(extravasation) into distal organs where they continue to proliferate forming a
second (metastatic) tumor mass. Cancer cell migration is typically regulated
by integrins, matrix-degrading enzymes, and cell-cell adhesion molecules [190].
In fact, anchorage independent growth is a hallmark of tumor cells.
1.2.4 Invasion of Cancer Cells of the Basement Membrane
Local invasion is critical for metastasis. The extracellular matrix and
the tumor have a profound influence on each other. During intravasation, de-
fined as the invasion of the cancer cell through the basal membrane into blood
vessels from a primary tumor or extravasation, defined as the exit from blood
vessels and colonization into a new site, tumor cells remodel their microenvi-
ronment through degradation of ECM components [15]. Cell invasion involves
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localized degradation of basement membrane, and a balanced expression of
ECM specific proteases and protease inhibitors [184]. Fibroblasts surrounding
the malignant epithelial cells, or the tumor cells themselve, secrete proteolytic
enzymes that degrade the ECM-cell associations [199], [240]. In most genetic
screenings of breast cancers, a class of proteolytic enzymes called the matrix
metallo-proteinases (MMPs), are often up-regulated [234], [213]. The MMPs
are zinc-dependent endopeptidases, collectively capable of degrading matrix
components such as collagen, laminin, fibronectin, and gelatin . At present,
21 members of the human MMP gene family are known [199]. Based on
their structure and substrate specificity, MMPs are classified into subgroups
of collagenases, stromelysins and stromelysin-like MMPs, matrilysins, gelati-
nases and membrane-type MMPs (MT-MMPs) [1]. MMP2 (gelatinase A, 72
kDa) and MMP9 (gelatinase B, 92 kDa) are pericellular proteinases that can
degrade type-IV collagen, the main constituent of basement membrane [181].
The MMPs are secreted as inactive zymogens (pro-enzymes) and subsequently
activated by multiple enzymes including cathepsins, trypsin, stromelysin 1,
MMP activity is under the stringent regulation of tissue inhibitors of MMPs
(TIMPs), and membrane-type MMPs (MT-MMPs) [108]. MMPs also release
anti-angiogenic factors like endostatin, angiostatin and tumstatin which may
explain the failure of broad spectrum MMP inhibitors as effective therapeutic
agents in the clinic because they may interfere with MMP mediated inhibition
of angiogenesis [113]. Specifically, MMP2 and MMP9 have established roles
in promoting metastasis as shown in a wide array of cancer models, human
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samples, and genetic screens [181]. Other enzymes that degrade the ECM in-
clude tissue serine proteinases (urokinase plasminogen activator, thrombin and
plasmin); the adamlysin related membrane protein (ADAM family); bone mor-
phogenic protein-1 type metalloproteinase; heparinase, and cathepsins, each
of which can be deregulated in various cancers [108], [63], [107].
1.2.5 Angiogenesis and Immune Surveillance
A progressively growing neoplasm requires adequate blood supply to
maintain its growth and metastatic potential. Once the existing tumor vas-
culature becomes insufficient, the tumor develops new vessels by a multistep
process that begins with the local degradation of basement membrane sur-
rounding the capillaries [84]. This allows the underlying endothelial cells to
migrate and invade the stroma and eventually proliferate to form a three di-
mensional network of new vessels [107]. Angiogenesis can be due to branching
of new capillaries from preexisting vessels (sprouting) or enlargement, splitting
and fusion from the walls of preexisting vessels (vasculogenesis) [108], [113].
Tumor cells secrete Vascular Permeability Factor (VPF/VGF), a heparin bind-
ing protein that targets VGFR expressing endothelial cell to proliferate [113].
Antiangiogenic agents act specifically to inhibit endothelial cell function and
thus impair neovasculogenesis [113].
Tumor immunology is a very critical field in cancer studies. The im-
mune system, specifically the T cells are relevant to human tumor immunology.
Genetic instability of tumor cells allow them to create various escape routes
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to by pass antigen specific T cell recognition [107]. Tumor cells lack antigens
that could be recognized by cytotoxic T cells and thus they gain a selective
advantage [43].
1.2.6 Genetic Signature for Lung Metastasis
The lung is one of the primary organs where breast cancer cells metasta-
size [213]. One emerging line of thought gaining prominence is that metastasis
is an earlier rather than late event. Genetic profiling and comparison of pri-
mary human carcinomas with lung metastases by various groups have provided
gene signatures that predict patient prognosis [139]. Although there is some
variation between signatures reported by different groups, there are several
overall common threads. Upregulation of these genes confers a growth advan-
tage to the primary tumor as well as distant metastatic colonies. One typical
lung metastasis profile lists several secretory and receptor proteins that al-
ter the microenvironment, such as EGF (Epidermal Growth Factor) family of
members (ligands for ErbB receptors), chemokines, MMP1, MMP2, vascular
cell adhesion molecule-1 (VCAM), cell differentiation inhibitors, prostaglandin
endoperoxide synthase, and cyclooxygenase 2 (COX2), amongst others [157],
[231].
1.2.7 Role of Endocytosis in Cancer
A newly evolving idea in cancer research is how cancer cells can derail
various steps of endocytosis. Primordial endocytosis was simply a means for a
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cell to procure nutrients from the environment [232]. As evolution progressed
towards more complex life-forms, endocytosis developed into a sophisticated,
opportunistic and dynamic signaling platform influencing a wide array of cel-
lular functions such as cell adhesion, proliferation, and migration. The main
purpose of endocytosis is to internalize, traffic, sort, recycle, and sometimes
scavenge the cell surface proteins, such as growth factor receptors, integrins,
transferrin receptors, adhesion junction proteins, and hormone receptors, thus
regulating their physiological levels and spatial availability [232], [56].
Most cells have multiple endocytotic portals. The best established
amongst them are clathrin mediated endocytosis (CME). Receptors are clus-
tered in clathrin coated pits, which are internalized as the membrane invagi-
nates. The resulting vesicles are cleaved from the rest of the membrane by
dynamins and fused with the early endosomes. The small GTPase Rab5 is es-
sential for both internalization and homotypic fusion with the early endosome
[9]). The cargo (receptor with associated molecules) is then sorted and routed
for recycling or lysosomal degradation [9], [116].
Phosphorylation of specific Tyr residues of EGFR (Epidermal Growth
Factor Receptor) targets it to coated pits, in a growth factor receptor-bound
protein 2 (Grb2) dependent manner [102]. Next, E3 ligase Cbl-mediated ubiq-
uitination allows EGFR to exit the early endosome [109]. Previously, it was
believed that endocytosis attenuates growth factor signaling. Recent evidence
suggests that endocytosis regulates spatio-temporal orientation of intracellular
signaling [9]. However, as in the case of EGFR, signaling from the endosomal
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complexes may be a function of the associated ligand [24]. For example, the
EGF-EGFR complex remains functional even in the low pH environment of
endosomes, while the TGFα-EGFR complex becomes progressively unstable
in acidic endosomal compartments and the ligand is promptly recycled back
to the surface thus creating an autocrine loop [11].
At the endocytic sorting level, tumor cells can have genetic defects in
Rab proteins whereby recycling is favored over degradation [177]. In fact,
Rab25, which critical for cargo recycling, is over-expressed in breast and ovar-
ian carcinomas [233], [31]. Other classic examples of such deregulation include
p38 kinase mediated phosphorylation of EGFR and modification Rab5 effec-
tors that alter the trafficking of the receptor and desensitize it from degradation
[73].
Lastly, much like the receptor tyrosine kinases (RTKs), labile adhesion
complexes comprised of integrins are also rapidly endocytosed and recycled
to the advancing front of the migrating tumor cell, facilitating anchorage and
traction of the lamellipodia. The dire consequence of deregulated endocytosis
of integrins and cell adhesion proteins could lead to increased metastasis due
to loss of normal apico-basal polarity (maintained by E-cadherins), subsequent
loss of cell-cell tight junctions, and increased dissemination of tumor cells [73],
[79].
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1.3 Migration
“Cell migration is a highly integrated multistep process that orches-
trates embryonic morphogenesis, contributes to tissue repair and regeneration,
and drives disease progression in cancer, mental retardation, atherosclerosis
and arthritis.”—Ridley 2003 , [190].
Cell motility is a recurring theme in the life cycle of a multicellular
organism and plays a major role in development, wound healing and immune
response. Firstly, during the gastrulation stage of embryogenesis, cells from
the ectodermal layer migrate to the endodermal layers. Next, during organo-
genesis of fruit fly or mammals, hematocytes, germ cells, border cells, and
tracheal cells migrate to specific sites guided by signaling mechanisms to de-
velop into tissues and organs [190]. Cell migration is also important for brain
development, especially for learning and memory functions [190]. In the cen-
tral nervous system, primitive nerve cells residing in the neural tube migrate
into the surrounding layers where they start forming dendritic networks con-
necting various areas of the developing brain. The synapses formed by these
extensions are important for development of the neocortex and hippocampus
centers for learning memory [74].
Importance of cell motility increases after birth of an organism since
tissue repair and wound healing require active cell migration [190]. Cellu-
lar movement, as observed during wound healing is efficiently reproduced in
vitro and utilized as a dependable, inexpensive assay for epithelial cell migra-
tion. The immune system also effectively utilizes the capacity of leukocytes
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to migrate out of the circulatory system to reach and destroy microorganisms
invading the surrounding tissue [190].
Migration is a tightly regulated invaluable process during development
and homeostasis [190]. A wide range of factors such as growth factors, actin
cytoskeleton, integrins and signaling kinases regulate cell migration. Clinical
outcomes of defective cell migration range from vascular disease, osteoporo-
sis, chronic inflammatory disease, rheumatoid arthritis, to multiple sclerosis,
mental retardation and cancer. All of these conditions can be attributed to reg-
ulatory defects in the cell migration pathway. In cancer, disseminated tumor
cells activate their inherent motility machinery to migrate out of circulatory
system and colonize in distant organs. Arguably, this can be the rate limit-
ing step in metastasis and hence is a good therapeutic window for metastasis
suppression strategies [207].
1.3.1 Mechanisms of Cell Migration
Cell migration is intrinsically dependent on extracellular cues provided
by the microenvironment, which dictates the direction of migration. Thus,
effective cell migration requires the integration of localized, transient signaling
events that will rapidly change the cellular architecture towards a more polar-
ized form in response to chemokine gradients. Cells reorganize their resting
actin cytoskeleton to form protrusions that will eventually provide an anchor-
age point for the bulk of the cell to move forward [190]. Based on various
in vitro and in vivo data, especially in developmental models, a blueprint of
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migration associated signaling has emerged that can explain how cells success-
fully convert a chemical input into a mechanical output.
In the next few paragraphs I will summarize the migration machinery,
starting with actin cytoskeleton and its polymerization and then briefly the
signaling aspect that choreographs the actin dynamics in a spatio-temporal
manner.
1.3.2 The Actin Machinery with the Heels and the Frills
Cell migration is a visually rewarding physiological process to study.
In this section I will discuss some of the distinguishing morphological charac-
teristics of a migrating cell that are typically used in the field as hallmarks of
migration. A clear understanding of the function of these cytoskeletal forms
will be helpful in analysis of our findings.
The cytoskeletal protein actin is ubiquitous in all eukaryotes and is the
key executioner of cell migration [190]. G-actin undergoes polymerization into
polarized helical filaments (F-actin) with a fast growing barbed end and a slow
growing pointed end generated via treadmilling. Under steady state conditions
actin treadmilling is a three step process [190].
1. Depolymerization from the slow growing pointed end, releasing ADP- G
actin.
2. Exchange of ATP for bound ADP, thereby restoring ATP-G actin.
3. Incorporation of the ATP-G actin at the growing end of actin filament.
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Upon receiving cues from the surrounding environment via integrins
and/ or RTKs, cells assemble actin filaments at specific sites that generate a
propulsive force in the direction of migration [190]. This dynamic actin as-
sembly is achieved by rapid polymerization of actin monomers at the ‘growing
end’ which are oriented towards the plasma membrane while the depolymer-
izing end faces the cytoplasm [190]. Actin assembly leads to formation of
membrane protrusions of two kinds, each serving a specific function. Since the
extension velocity of the broad lamellipodia is closely equivalent to the rate by
which the barbed ends grow, one can conclude that these structures are the feet
that move the cell. The filamentous filopodias, on the other hand, are sensors
that detect the chemokine gradient and navigate the direction of motion [146].
Cytoskeletal actin undergoes massive reorganization during migration. Sim-
ple globular actin monomers undergo polymerization and cross-linking form a
mesh work that facilitates migration. Regulation of actin reorganization com-
prises a coordinated interplay of a large repertoire of actin binding proteins
that segregate as either, a) nucleating proteins such as Arp2/3 and formin,
b) depolymerizing proteins like the cofilin family members, and c) capping
proteins namely gesolin and more recently EPS8 (Epidermal Growth Factor
Substrate 8). Upstream events that promote such binding interactions with
actin are generated by activated RTKs [190], [177], [126], [2].
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1.3.3 Dynamics of Cell Migration
At the cytoskeletal level, migration proceeds through the cyclical set of
events discussed below and depicted in Fig. 1.2.
Figure 1.2: Steps in Cell Migration.
Various cyclical steps leading to cell migration.Adapted from www.wisc.edu,041509
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Polarization
Under quiescent conditions, an epithelial cell maintains strong cell-cell
and cell-ECM adhesions and the cytoskeleton is evenly distributed [190]. When
the cell is stimulated by growth factors, it overcomes the cell-cell and cell-ECM
adhesions and reorganizes its skeletal structure into a forward moving front and
a retracting rear end. Distinct signaling events such as receptor endocytosis
and vesicular transport, phosphatidylinositol 3-kinase (PI3K), integrins and
Rho family GTPases, including Rac, maintain the polar status of the cell
during migration [190].
Cdc42, PAR proteins (PAR6 and PAR3) and atypical protein kinase
(aPKC) are involved in the initial polarization process. PI3K, commonly ac-
tive only at the leading edge and inactivated by a specific phosphatase PTEN,
plays a critical role in maintaining apico-basal polarity. Interestingly, muta-
tions in genes that maintain such polarity, by virtue of appropriate E-cadherin/
beta-catenin adhesion signaling, are also found to activate c-Jun N-terminal
Kinase(JNK) [93], a MAPK family member previously associated with ’ep-
ithelial planar-polarity’ pathway in Drosophila.
Protrusion
The first sign of migration is visualized when the polarized cell puts
a ’step forward’ in the form of a protrusion, utilizing the actin cytoskele-
ton. Intracellularly, the actin filaments are oriented such that the fast-growing
“barbed” end faces the region of the plasma membrane transmitting the extra-
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cellular stimuli while the slow-growing “pointed” end faces the rear end of the
cytoplasm [190]. This treadmilling provides an inherent drive for membrane
protrusion by increasing the rate of actin turn-over leading to unidirectional
membrane protrusion. Typically, the growth of the barbed end is restricted
when capping proteins such as gelsolin or EPS8 bind to the barbed-end, sev-
ering the spontaneous growth of the actin filament [190].
Actin depolymerizing proteins, namely ADF/cofilin, bind and atten-
uates the growth of the filament [249]. Profilin targets actin monomers to
barbed ends thereby preventing self-nucleation. Together, these factors main-
tain a dynamic intracellular pool or freely available actin. The rate limiting
step in the treadmilling process, as discovered from in vitro studies, is depoly-
merization at the slow pointed end.
Cytoplasmic protrusions can either be spiky filopodia, where actin fila-
ments form long parallel unipolar bundles, or large, broad lamellipodia, where
radial and rib-like organization actin filaments to form a branching dendritic
network [225]. Functionally, sensory filopodias are utilized to explore the lo-
cal environment, whereas the branched design of the lamellipodia forms broad
protrusions in the direction of migration to provide a strong foundation over
which the cell can move forward. The expanding lamellipodium often cause
the plasma membrane to form ruffles at the leading edge. Such visible pe-
ripheral ruffles are a hallmark of newly polymerized actin that enables cell
migration [190], [225].
In the lamellipodia, actin related proteins (Arp2/3) that resemble actin
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monomers, bind to the sides of actin and provide a site for nucleation [225].
New side branches then arise at a 70 ◦ angle from the ‘mother’ actin filament
forming a highly branched, wide mesh work. The Arp2/3 complex is acti-
vated locally at the cell membrane by Wasp/Wave family members which are
themselves major targets for Cdc42 and Rac [190]. Lamellipodium are sta-
bilized by cross linker proteins such as cortactin, filamin A and alpha-actinin
[225]. Directly upstream of such dynamic actin organization are small GT-
Pases of the Rho family, particularly Rac. Evolutionarily conserved Rac is
a monomeric switch that interchanges from an inactive GDP-bound state to
an active GTP-bound state. The GTP-GDP inter-conversion is catalyzed by
guanine nucleotide exchange factors (GEFs), guanine nucleotide dissociation
inhibitor (GID), and GTPase activating proteins (GAPs). Rac activation is
regulated by signal transducing proteins such as Ras, PI3K, Grb2 and EPS8
which are implicated in the spatio -temporal regulation of ruffle formation
[190].
Traction
In order for the cell to advance, the newly created protrusions form focal
points of attachment with the matrix and provide a stable fulcrum for the cell
to pull itself forward. Tractional forces are created at sites of adhesion by the
contractile properties of myosin II. Importantly, the adhesions turnover at the
leading edge and disassemble at the trailing end in response to extracellular
cues regulate cell motility [225].
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In addition to RTKs which transmit extracellular chemical cues to the
cytoskeleton, the extracellular matrix transmits physical adhesion dependent
cues to actin machinery via a large family of transmembrane proteins called
integrins. Integrins provide traction sites and act as mechanosensors to trans-
mit information about surface topography [225], [91], [84]. Integrins are het-
erodimeric proteins with a short intracellular domain and long extracellular
domain [70]. Ligand binding induces conformational changes that are trans-
mitted to the cytoplasmic domains. Integrin clustering activates intracellular
signaling cascades, altering the rate of phosphoinositol lipid synthesis and
small GTPases activation [3] to affect cell polarity, adhesion junctions, and
the dynamic of arrangement of the cytoskeleton. Specifically, focal adhesion
junctions formed by integrins activate intracellular signaling pathways such as
Ras-Raf-ERK, akin to growth factor receptors [14] [24].
Normally, non-migratory or slow moving cells display focal adhesions,
large integrin clusters that are tightly adherent and dependent on Rho-stimulated
myosin contractility [190]. In contrast, Rac and Cdc42 dependent small ad-
hesions, or focal complexes, are at the leading edge of migrating cells to sta-
bilize lamellipodia and contribute to efficient migration [23]. Rho GTPases
are critical effectors in this process. These GTPases are controlled by signals
emanating from adhesion-related signaling modules, such as a multi-protein
complex that includes Focal adhesion kinase (FAK), Src, paxillin, Crk, Crk
associated substrate (CAS), p21 associated kinase (PAK), and mammalian
G-protein-coupled receptor kinase interactor 1(GIT) [225].
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Retraction
During translocation, cell-ECM adhesions at the cell’s rear end dis-
assemble allowing the trailing edge to retract. Calpain like proteases cleave
integrin junctions and downregulate adhesion protein talins, allowing the cell
to detach from the matrix and move forward [190]. This retraction process is
dominated by myosins instead of actins [23]. Components of the adhesion com-
plex are endocytosed with the active involvement of dynamin [190]. RhoA and
Rac and PAK come into play and phosphorylate myosin light chain (MLC),
allowing myosin fibers to contract. Once the rear adhesions are released, the
frontal protusions enhance the cell polarization. This maintains a positive
feedback for migration to continue.
1.3.4 Barbed End Cappers
Barbed end capping proteins play a very significant role in cell mi-
gration. Their activity and association with actin are directly regulated by
signaling cascades. Functionally, these proteins maintain a steady state con-
centration of monomeric G actin during the resting and motile state of the
cell. Within a lamellipodia, capping proteins directly fine-tuned growth, half
life and length of actin filaments in a signaling specific, spatially restricted
fashion.
Therefore, dissociation of capping proteins provides a platform for fur-
ther actin polymerization on the existing filaments, such as in a protruding
lamellipodia [71]. Common examples of capping proteins include gelsolin fam-
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ily members namely, severin, adseverin/scinderin, villin and fragmin, Cap Z
and Cap G [185] [191]. Interestingly, capping proteins are also decisive factors
in the type of cytoskeletal protrusion a cell chooses to make. For example, sup-
pression of capping action generated filopodia while reducing the formation of
lamellipodia in several cell lines [74].
1.3.5 Signaling During Cell Migration
Multistep signaling pathways leading to cell migration are under strict
spatio-temporal regulation by actin binding proteins which also moon-light as
signaling elements in various pathways. Both in normal and cancer cells, mi-
gration is initiated by ligand binding and executed by small GTPases like Ras
and Rac. Extracellular ligands can be growth factors such as EGF, platelet
derived growth factor (PDGF), hepatocyte growth factor (HGF), transform-
ing growth factor α/β (TGF α/β) which bind to RTKs (Receptor Trosine
Kinases) [36]. Also matrix proteins which bind to cell surface integrin recep-
tors, especially αV/β3 in the case of breast cancer, are activators of migration
[4].
Ligand binding to RTKs causes receptor dimerization, subsequently
activating cytoplasmic kinase domain via auto-phosphorylation of tyrosine
residues. This allows binding of several Src homology or SH-2 domain con-
taining adaptor proteins, thus setting the stage for formation of various multi-
protein complexes which amplify and diversify signals to specific downstream
effectors [159].
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Figure 1.3: Growth Factor Signaling During Cell Migration.
Sensing a chemokine, the RTKs of a migrating cell dimerize and trigger a signaling
cascade to activate Ras and Rac GTPases. Downstream of Ras both ERK (via Raf) and
JNK (via Rac) are activated. Finally activated Rac induces actin remodeling in a site
specific manner at the leading edge of the migrating cell.
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The most indispensable SH-2 containing protein that links RTK sig-
naling to Rac is the Class I PI3K. The p110 catalytic subunit phosphory-
lates phosphatidylinositol 4,5 diphosphate (PIP2) to phosphatidylinositol 3,4,5
triphosphate (PIP3) upon membrane recruitment and binding of the regu-
latory p85/p55 subunit [172]. Alternatively, p110 can directly bind to the
activated small GTPase, Ras and induce a cell migration phenotype via Ras-
Raf-ERK pathway [190]. Activation of GDP-Ras in response to mitogenic
signals requires a switch between GDP and GTP. Post RTK activation, gua-
nine nucleotide exchange factors like Son of Sevenless1 (SOS1) are recruited to
the plasma membrane, proximal to Ras, by adaptor proteins like Grb2. This
allows SOS1 to catalyze the GDP-GTP switch mentioned earlier. Concomi-
tant binding of PI3K to GTP-Ras via its p110 catalytic subunit, and to RTK
via its p85 unit leads to its optimal activation and intracellular signaling. Ac-
tivation of Rac, downstream of Ras, promotes de novo actin polymerization at
the cell periphery to form lamellipodial extensions and membrane ruffles via
sequential activation of PAK (P21 Associated Kinase) and JNK [190]. Activa-
tion of another Rho family member, Cdc42, triggers actin polymerization to
form filopodia or microspikes downstream of the Ras-Raf pathway [191].
Rac, in turn, orchestrates actin polymerization by positively regulat-
ing the levels of actin binding proteins like profilin and Arp2/3 to facilitate
polymerization at the barbed-end of filaments or downregulate molecules like
thymosins that inhibit actin polymerization [182]. Finally, Rac activation is
closely associated with membrane ruffling at the leading edge due to the folding
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of the non-adherent lamellipodia, validating its critical role in cell migration.
Thus Rho-GTPases (22 members in the Rho family including Rac) are mas-
terminds of actin-based motility. In addition, they play roles in cell cycle
progression, gene transcription and vesicular trafficking.
1.3.6 Pathobiology
Several proteins that regulate cell migration are critical for embryonic
and fetal development. Defects in these proteins can manifest very early and
can lead to the failure of blastocyst implantation into the uterus, resulting
in early loss of pregnancy [190]. At later stages in development, defects in
proteins regulating migration can result in embryos with disorganized tissues
because their component cells have failed to travel to the correct location or,
despite having traveled along the right path, they fail to form the appropriate
connections with neighboring cells and their surroundings. Abnormalities that
do not result in early fetal death can lead to a number of congenital abnor-
malities in brain development - such as epilepsy, focal neurological deficits and
mental retardation- and heart development [190].
Cell migration also has a central role in chronic inflammatory condi-
tions. Asthma causes chronic inflammation of the airways which results from
an ongoing immune response to foreign materials (allergens) inhaled from the
environment. The constant presence and activation of white blood cells in the
airways of asthmatics causes tissue damage, leading to hyper-reactivity of the
airways to otherwise innocuous stimuli such as exercise, stress and cold air. In
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rheumatoid arthritis, the constant destruction of joint tissue by inflammatory
cells migrating into these compartments results in compromised limb function
and crippling pain [190].
1.4 c-Jun N Terminal Kinase (JNK)
1.4.1 Discovery of JNK
c-Jun N terminal Kinase (JNK), a member of MAPK family (MAPK8/
MAPK9), is conserved throughout eukaryotic evolution from yeast to humans
[42]. JNK signaling pathway is used by cells to respond to stress. Hence, this
kinase is also known as stress activated protein kinase (SAPK) [42]. In 1994,
Kyriakis et al. identified the p54 isoform of JNK from cyclohexamide treated
rats. JNK was shown to be a proline-directed kinase akin to the other MAPK
family member ERK1/2, but requiring a unique Thr and Tyr dual phosphory-
lation for its activation and had distinctly high substrate affinity toward c-Jun
[17], [117]. Subsequently, a wide variety of nuclear and cytoplasmic substrates
and a gamut of physiological/pathological processes have been associated with
JNK signaling [17].
1.4.2 Causes and Consequences of JNK Activation
In response to specific extracellular stimuli, RTKs at the cell membrane
trigger the Rho family of GTPases. Rho proteins then stimulate the three
tiered, MAPK cascade starting with the MAPKKKs (MAP kinase kinase ki-
nase) which includes MEKK (MAP kinase kinase) family proteins, apoptosis
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signaling kinases (ASK), mixed lineage kinases (MLK) [17], [18]. MAPKKKs
subsequently activate the next level of kinases consisting of MKK4 or MKK7
via dual phosphorylation. The MKK4 and MKK7, in turn, activate JNKs via
dual phosphorylation of threonine and tyrosine residues. Notably, MKK4 and
MKK7 activate JNK in the cytoplasm and the nucleus. Once activated, JNK
translocates to the nucleus, where it phosphorylates and activates transcrip-
tion factors like c-Jun, Jun B, Jun D, ATF2, Elk-1, and STAT3 (Fig. 1.4).
Other potent activators of JNK are UV, ROS (reactive oxygen species), thiol-
reactive compounds, pH, hypo- or hyper- osmolarity and Tumor Necrosis Fac-
tors α (TNFα). Since JNK can affect a wide variety of cellular substrates
and transcription factors, it plays a major role in development and diseases
[17]. Activation of JNK can lead to various pathological conditions as listed
in Table 1.1 [17].
Using jnk3-/- mice, which are developmentally normal and viable, Davis
et al. provided direct evidence that JNKs are involved in stress-induced AP-
1 (Activator Protein 1) transcriptional activity [42]. JNK signaling can also
affect gene expression via additional cytoplasmic mechanisms such as regulat-
ing protein stability and nuclear transport [198]. Specifically, JNK2 mediated
phosphorylation of c-Jun at Ser63 and Ser73 targets c-Jun ubiquitination and
degradation (by Itch3 ubiquitin ligase), thus decreasing its stability and AP-1
transcriptional activity [198].
Interestingly, JNK activity is also involved in repression of transcrip-
tional activity. For example, JNK inhibits the activity of a specific nuclear
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Table 1.1: Pathological conditions associated with JNK
Disease JNK isoforms Correlation Reference
Parkinson disease JNK1/JNK3 +/+ Hunot et al., 2004
Stroke JNK3 + Kuan et al., 2003
Axotomy JNK2/JNK3 +/+ Keramaris et al., 2005
Bone remodeling and
joint disease
JNK1 + David et al., 2002
Obesity and type 2
diabetes
JNK1 + Hirosumi et al., 2002
Type 1 diabetes JNK2 + Jaeschke et al., 2005
Atherosclerosis JNK2 + Ricci et al., 2004
Abdominal aortic
aneurysm
JNK2 + Yoshimura et al., 2005
Cardiac hypertrophy
and ischemia
JNK1/JNK2 +/+ Ferrandi et al., 2004
Liver Disease JNK1/JNK2 +/- Qiao et al., 2003
factor of activated T cell transcription factors, named NFAT4 (Nuclear Factor
for Activated T-cell), which remains in a latent form in the cytoplasm of quies-
cent cells [42]. JNK induced phosphorylation inhibits its nuclear translocation,
thereby hindering transcriptional activity. Activated JNK also has cytoplas-
mic substrates like FAK (Focal Adhesion Kinase), and paxillin. Paxillin is
a key protein in cell migration pathway [91], while FAK regulates adhesion
turnover uring cell migration [190], [14]. In conclusion, activation of JNK can
lead to a plethora of downstream consequences which demands for modulators
that will render specificity and aid in coordination of signaling modules.
Signaling specificity in MAPK pathways is achieved by the presence
of scaffolding proteins, such as the JNK-interacting protein-1 (JIP-1), in the
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case of JNKs. Under normal physiological conditions, full-length JIP-1 binds
to JNK, MKK4, and c-Jun, ensuring physical proximity that facilitates phos-
phorylation of the substrate [17]. The translocation of activated JNKs into
the nucleus is also controlled by JIP, in that JIP retains JNK in the cytoplasm
[17] by keeping it engaged in complexes with its upstream kinases [10]. JNK
can also be inactivated by Ser/Thr and Tyr protein phosphatases specifically
by dual specificity Ser/Thr/Tyr MAP kinase phosphatases, (MKPs) [17].
1.4.3 Mechanism and Kinetics of JNK Activation: Sustained vs.
Transient
Data from solid-state kinase assays demonstrate that JNK has substrate
docking sites distinct from catalytic pockets, which helps JNK recognize its
substrates by virtue of a docking motif, or D domain, with a consensus se-
quence: (K/R)2-3-X1-6-f-Xf [238]. Biochemical studies have implicated that
the amplitude and duration of JNK activation is a critical determinant of
downstream cell signaling decisions [17]. However, this aspect of JNK signal-
ing is not well defined. It is probable that a fine balance between activating
MKKs and inhibiting MKPs (MAP Kinase Phosphatases) determine the fi-
nal biological outcome. Specifically, transient activation of JNK is necessary
for liver regeneration and TNFα induced proliferation, whereas, intense and
sustained activation is involved in apoptosis [133].
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Figure 1.4: Overview of the JNK pathway showing various stimulus and iso-
form specific functions of JNK. Modified from Bogoyevitch and Kobe 2006.
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1.4.4 An Overview of JNK Isoforms
The JNK proteins are encoded by three genes. The jnk1 and jnk2 genes
are expressed ubiquitously while jnk3 expression is limited to neuronal tissue,
testis and cardiac myocytes [42]. Each jnk gene is localized on a different
chromosome. In mice, jnk1 is on chromosome 14, jnk2 on chromosome 11, and
jnk3 on chromosome 5. In humans the respective locations are 10q11.22, 5q35
and 4q21.3 (http://www.ncbi.hlm.nih.gov/ entrez). Alternate splicing of jnk1,
jnk2 and jnk3 mRNA occurs either at the center (corresponding to α and β
isoforms) or at the C-terminus (corresponding to 1 and 2 isoforms) resulting
ten spliced variants as depicted in Fig.1.4. Although there is >80% sequence
homology amongst these isoforms, they are functionally distinct. The second
type of alternative splicing involves mutually exclusive utilization of two exons
in the kinase domain in the jnk1 and jnk2 transcripts which has functional
consequences by altering their interactions with substrates [17]. Hence, JNK1α
and JNK1β differ from JNK2α and JNK2β based on substrate specificity [198].
JNK3 has only two variants, a 57 kDa (JNK3α) and a 49 kDa (JNK3β).
Notably, mice lacking any individual jnk gene are viable, but if both jnk1 and
jnk2 are absent embryos die during mid-gestation due to defective neural tube
closure and brain abnormalities [42], [235]. Several lines of evidence indicate
that jnk2 gene may play a more significant role in cancer. For example, in-
creased expression of the 55 kDa JNK2 isoform was observed in glial tumors
and slower tumor development in jnk2-/- mice occurs in a chemically induced
skin carcinoma model [29]. Recently, Wong et al. reported that anti-sense
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mRNA against JNK2, and not JNK1, inhibited transformation of lung carci-
noma and glioblastoma cell lines, supporting a tissue specific function of JNKs
[7].
1.4.5 Enigmatic Role of JNK in Tumorigenesis and Metastasis
JNK signaling regulates both apoptosis and proliferation. Therefore,
its role in cancer is enigmatic. Both tumor-promoting and tumor-suppressing
functions have been ascribed to JNK pathway components. Overall, from the
perspective of tumor biology, importance of JNK is in mediating transforming
actions of oncogenes such as Ras [17], Bcr-Abl [17], and Met [187], [195]. Anti-
sense JNK oligonucleotides were found to inhibit the growth of tumor cells
(PC12, A549, HeLa, and MCF-7) [183] and constitutive activation of JNK in
glial tumor cell lines support that JNK plays a role in promoting tumorigenesis
[222]. Furthermore, critical mediators of cell migration and invasion such as
Rac, FAK, and Src can also activate JNK in response to growth factors [37].
JNK expression was correlated with enhanced tumor growth in prostate [244],
brain [7] and glial tumors [222]). Recently, in a clinical study with 68 human
patients, investigators compared the levels of phosphorylated (activated) JNK,
ERK and p38 kinase in paired cancer and non-cancer breast tissues [247].
They reported that tumors with lower levels of pJNK in DCIS lesions were
associated with longer overall patient survival, suggesting that activated JNK
facilitates tumor progression [247]. However, activation of JNK can have both
pro-proliferation or anti-proliferation effects in human cancers, depending on
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cell type and its cross talk with other kinases [42].
A few examples discussed in this section, from Drosophila and mam-
malian models, highlight a possible role for JNK in promoting metastasis.
In Drosophila, JNK controls migration, invasion and EMT [180]. Normal
development of Drosophila is aided by characteristic apico-basal polarity of
epithelial cells, which is slowly lost as they progress towards a malignant phe-
notype. In a Ras-induced Drosophila eyelid tumor model, loss of cell polarity
contributes to the malignant phenotype by activating Drosophila JNK (Bas-
ket), and subsequent inactivation of E-cadherin and β-catenin. Other studies
reported a causal relationship between JNK activation and accelerated tumor
growth [93].
Unlike Drosophila, mammals have multiple isoforms of JNK with over-
lapping and contradictory functions [42]. Weston et.al., showed a delay in
eyelid closure of jnk1-/-jnk2+/- mice compared to their jnk1+/+/jnk2+/-
littermates [238]. Since eyelid closure is a function of corneal epithelial cell
migration, this implicates jnk1 in embryonic epithelial cell migration [238].
JNK2 isoforms on the other hand, are implicated in tumorigenesis via acti-
vation of Akt and over expression of eukaryotic translation initiation factor 4
(eIF4E) in a human glioblastoma model [7].
JNK is activated downstream of ECM-integrin interaction via the FAK,
Ras-PI3K-Rac signaling pathway, suggesting a role in tumor stroma interac-
tions [3]. In absence of serum, JNK stimulates survival signals in fibroblasts as
a specific response to fibronectin, a critical component of ECM. Breakdown of
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the ECM is accomplished by the concerted action of several proteases, includ-
ing the urokinase plasminogen-activator (uPA) and MMPs, which are crucial
for cancer invasion and metastasis. Direct evidence for involvement of JNK
in the proteolytic cell invasion process is less abundant in the literature, al-
though its involvement in the regulation of MMP9 has been reported [8], [188].
Expression of MMP9 is regulated by two well-characterized AP-1 sites in its
promoter. JNK phosphorylates c-Jun, a known component of AP-1 complex.
Elevated JNK signaling may contribute to increased MMP9 expression and
activity, enhancing ECM degradation and increasing tumor cell invasion [32],
[199]. In human trophoblastic cells, TNFα induces MMP9 expression, secre-
tion and activity are regulated by the JNK-AP-1 pathway [32].
Both stress- and cytokine-induced JNK activation requires MKK4, an
upstream kinase that preferentially activates JNK via Tyr residue [251]. The
MKK4 chromosomal locus proximal to p53 (10cM centromeric to p53 gene) is
often mutated in colon, breast and pancreatic carcinomas [220]. Since MKK4
is a tumor suppresor, its loss will also induce JNK signaling, promoting tu-
morigenesis.
1.4.6 Pharmacological inhibitors of JNK
The global purpose of this study was to determine the contribution
of JNK in cancer so that highly specific JNK inhibitors can be developed as
therapeutic agents. The two small-molecule kinase inhibitors commonly used
to attenuate the activity of all JNK proteins are SP600125, an anthrapyralo-
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zon, which significantly inhibits JNK1, 2, and 3 (Ki = 0.19 M) activity. The
inhibitory mechanism of SP600125 is by reversible competition with ATP for
binding in the active site [12], [114]. SP600125 is used extensively in cells to
inhibit the phosphorylation of downstream targets of JNK [12]. However, the
specificity of SP600125 is a concern. At higher concentrations its inhibitory
effects may also apply to ERK and p38 kinase pathways [168].
An attractive and efficient alternative to SP600125 is a 21-amino acid
peptide inhibitor of activated JNK. In 2002, Barr et al., synthesized this pep-
tide analog based on amino acids [10] of the JNK-binding domain (JBD) of
the JNK scaffolding protein, JIP-1. When the JIP-1 protein is truncated, such
that it can only bind JNK, no further phosphorylation of JNK substrates can
occur [10]. In vitro recombinant protein studies using JNK substrates such
as c-Jun, ATF-2 and Elk confirmed up to 90% suppression of JNK activity
with this peptide (at 4-25µM concentration range) [10]. The tethering of a
TAT-sequence to the truncated-JIP increases cell permeability of this small
peptide, making it a promising candidate for future drug development [132].
1.5 Epidermal Growth Factor Receptor Substrate 8 (EPS8)
1.5.1 A Brief History of EPS8
In the early 1990s, EPS8 was identified as a novel biological substrate
of EGFR [58]. In the context of RTK signaling, the existing pool of cellular
second messengers that elicit mitogenic effects upon receptor activation include
PLC- phospholipase C [227], p21 Ras GTP activating protein [115]Raf [165],
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and p85 subunit of PI3K [210]. However, data from murine fibroblasts show
that EGFR is incapable of efficient binding to most of the aforementioned
second messengers [57]. In order to identify alternate second messengers for
EGFR, Fazioli et al. developed a method by which intracellular substrates of
EGFR could be cloned directly. They purified entire sets of proteins that were
Tyr phosphorylated upon receptor activation and generated antisera against
the entire pool of proteins. This allowed them to characterize substrates and
screen cDNA libraries. They isolated a novel gene product,EPS8, which is a
821 amino acid protein about 97kDA in size with an additional minor 68kDA
component and named it EPS8 [57]. The two proteins are isoforms arising out
of an alternatively spliced mRNA. Based on binding studies, direct association
between EPS8 and EGFR was reported to be not very robust in vivo [57].
Castagnino et al. reported that EPS8 binds stably to the juxtamembrane
region of EGFR [28] in a pTyr and SH2 independent manner, arguing the
importance of EPS8 tyrosine phosphorylation.
It was a matter of time before other activators of EPS8 would surface.
Indeed, in NIH3T3 cells both PDGF and αFGF, but not insulin, induced
robust Tyr phosphorylation of EPS8 [72]. This early observation fails to get
much attention in the subsequent EPS8 literature but becomes relevant in my
research by expanding the scope of EPS8 as a growth factor receptor substrate
beyond EGFR. Lastly, it needs to be mentioned that there are other members
in the EPS8 family, namely EPS8-like protein 1, 2 and EPS8 [206]. However,
they are functionally not well characterized, and hence not a part of this study.
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1.5.2 Structure of EPS8
Most second messengers recognize and bind to phosphorylated Tyr-
residues on RTKs via an SH-2 domain [202]. EPS8 lacks an SH2 domain
and instead contains an SH3 domain [58] which recognizes proline-rich regions
[189]. Other domains of EPS8 include a nuclear targeting domain and a split
putative PH (pleckstrin homology) domain. The carboxy terminus houses the
SH-3 domain, also called the effector region. EPS8 interacts with various sig-
naling proteins such as Shb (Karlsson1995), Shc [151] and RN-Tre [130] via its
effector region to regulate growth factor signaling and trafficking [204], [206].
Mutations in this effector region have dire consequences such as incomplete
oocyte maturation in Xenopus or inhibition of Fos-directed transcription in
mammalian cells [58]. The 586-821 sequence within this region binds to actin
and elicits actin remodeling. The NH2 terminus of EPS8 is proline rich and
inhibits the activation of the carboxy end under resting conditions [206]. This
regulatory auto-inhibition is relieved once EPS8 binds to RTKs which forcibly
opens up the effector domain allowing downstream signaling [28].
1.5.3 Cellular Localization,Expression and Interactions of EPS8
EPS8 is typically localized in the perinuclear region of resting cells
[206]. Upon growth factor stimulation it redistributes to plasma membrane,
especially at the sites of active actin reorganization including membrane ruffles
[48]. Once again, the effector region of EPS8 is responsible for its localization
and is sufficient to induce membrane and dorsal ruffles even in the absence of
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growth factors [206].
Due to its unique structural characteristics, EPS8 participates in exten-
sive networks with a wide array of substrates ranging from signaling molecules,
scaffold proteins, kinases and cytoskeletal [205]. Activation of EPS8 is sensi-
tive to the concentration of growth factor ligands and receptor occupancy
[57], [151]. Thus EPS8 can sort incoming growth factor signals, possibly based
on their intensity, and direct signals into various molecular circuits leading to
amplification of mitogenic inputs or reorganization of cytoskeleton [128], [129].
A third outcome can be transcriptional modulation of cellular differentiation
[206].
A few examples of the diverse physiological outcomes of EPS8 activity
include Src-mediated [136] transformation of cells, Rac-mediated [129], [49]
actin remodeling and migration, and disheveled (Dsh)-mediated gastrulation
[97]. Thus far, studies show that the functional outcome of EPS8 signaling
is dictated by its participation in specific complexes. To simplify matters we
have classified its binding partners based on the three interacting domains.
Binding via SH3 domain: E3b1(Abi1), RN-Tre, Shc, Shb Actin Reor-
ganization.
Binding via NH2 terminal proline rich domain: Src, IRSp53.
Binding via split PH domain: Membrane Anchoring.
EPS8 is involved in multiple signaling complexes and is constitutively
phosphorylated in human tumor cell lines with striking propensity [229], [239],
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Figure 1.5: EPS8 Binding Interactions.
EPS8 is a multinetworking protein and can bind to various substrates via its SH3
domain or C terminal effector domain. Physiological function of many of the EPS8 binding
interactions are unknown.
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[145]. A small fraction of EPS8 can bind to p52 and p46 Shc in a pTyr inde-
pendent manner via EPS8’s SH3 domain augmenting Ras signaling [151]. In
vivo evidence of EPS8-Shc interaction correlates with a malignant phenotype
by facilitating trnasformation induced by Src signaling [136], [151].
1.5.4 The EPS8-Abi1-SOS1 Binding Complex
One of the most critical binding interactions for this project is the
EPS8-Abi1-SOS1 binding complex. The importance of this complex in trans-
ducing signals from membrane to the cytoskeleton is profound. SOS1 is a
GEF (Guanine Nucleotide Exchange Factor) with two GEF activity motifs
that activate Ras and subsequently Rac [171]. EPS8 is the binary switch that
sequentially tethers Ras and Rac to SOS1, allowing GEF actions on the two
Rho GTP proteins, which are critical for actin remodelling. Genetic deletion
studies showed that EPS8 is directly responsible for activation of SOS1 [45].
Since the affinity of SOS1 for the effector region of EPS8 is rather low, there
is a physiological need for a scaffold protein to enhance their binding [204].
Abi1 serves this purpose and also increases the local concentration of the two
proteins to a stoichiometry sufficient for mitogenic response [206]. EPS8 fails
to complex with SOS1 in the absence of Abi1 [205]. Finally, biochemical and
biological evidence showed a quaternary complex, simultaneously involving
PI3K, EPS8, Abi1, and SOS1, is essential for activating the GEF activity of
SOS (Son of Sevenless) [205], [96].
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1.5.5 Role of EPS8 in Regulating Actin Remodeling
Actin remodeling is stimulated by growth factor signaling cascade lead-
ing to activation of Rho GTPase family member Rac. EPS8, by binding to
actin through its C-terminal effector domain, can localize Rac signaling and
regulate actin remodeling during cell migration [196] as evidenced by increased
formation of actin cables in cultured cells upon EPS8-Abi1 stimulation [204].
Palladin, a widely expressed phospho-protein that plays an important role
in organizing the actin cytoskeleton was found to co-localize with EPS8 at
dynamic membrane ruffles [72]. In response to PDGF and phorbol ester treat-
ment, EPS8 and palladin induce rapid and transient remodeling of the actin cy-
toskeleton promoting the formation of highly dynamic membrane protrusions
which are early indications of lamellipodia formation [72]. Another critical role
of EPS8 is in actin capping [33]. The C-terminus fragment of EPS8 can effec-
tively cap the barbed end of actin filaments in a Abi1 dependent manner,and
since capping regultes extension as well as branching of actin filaments during
lamellipodia formation, this is another mechanism by which EPS8 can relegate
cell migration [196], [33]. Interestingly, this function of EPS8 is independent
of Rac activation [196].
1.5.6 An Overview of the Role of EPS8 in RTK Signaling and Traf-
ficking
EPS8 is a molecular switch that transduces signals from activated RTKs
to small GTPases Ras and then Rac, eventually resulting in actin cytoskele-
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tal reorganization[206] as depicted in Fig.1.6. GEFs are important signaling
intermediates in this cascade because they catalyze the exchange of GDP for
GTP to control the rate and timing of activation of Ras and Rac [205].
Figure 1.6: EPS8 Mediated EGFR Signaling.
EPS8-SOS1-Abi1 complex is essential for SOS1 to activate Rac. This complex transmits
signals from membrane bound RTK to the actin cytoskeleton.
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Figure 1.7: EPS8 Mediated EGFR Trafficking.
EPS8 binds to Rab5 Gap, RN-Tre via its SH3 domain. EPS8-RN-Tre interaction
inhibits Rab5 mediated EGFR internalization.
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Role in RTK Signaling
Ligand binding causes dimerization and Tyr phosphorylation of RTKs.
Second messengers (Ras and Rac),and GEFs (SOS1) are recruited to the mem-
brane by adaptor proteins to allow signal transmission from the membrane
[9],[24]. Activated RTKs recruit the adaptor protein Grb2 (via SH2 domain)
and its cargo, SOS1 to the membrane. Grb2 binds to SOS1 constitutively
via a SH3 domain which is recruited to the membrane upon EGFR activation
[96]. Once at the membrane, dual GEF function of SOS1 catalyzes GDP-GTP
exchange on membrane bound Ras [96]. Activated Ras then directly binds
to PI3K [96], initiating a mitogenic signaling cascade leading to downstream
activation of ERK and Akt [233]. The Ras/PI3K interaction is essential for
further propagation of the signal to the level of downstream Rac [96], [95] as
shown in Fig.1.6.
SOS1 also binds to Abi1 via the SH3 domain, an interaction not ter-
minated by RTK activation [130]. When EPS8 enters this complex, SOS1 un-
dergoes conformational changes that can activate Rac, using its second GEF
function [129]. While the Cdc25-like domain on SOS1 is responsible for ac-
tivity of Ras, and a second DH-PH tandem domain is specific for the Rho
protein, activates Rac [128], [45]. Finally, active GTP-bound Rac leads to
actin remodeling [48]. Interestingly, JNK is also a downstream effector of Rac
pathway [206] and is often used as an indicator for Rac activation.
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Role in Intra-Cellular Trafficking
Ligand-bound EGFR internalizes via clathrin coated pits and is re-
cruited to early endosomes [9]. EGFR is also recycled in a spatio-temporal
fashion, affecting cell polarity based on a chemokine gradient [116]. Alterna-
tively, EGFR is relegated to the late endosome and lysosome for degradation
[116]. Receptor trafficking is mediated by Rab GTPases. Specifically, Rab5
has comparatively a high intrinsic GTPase activity and regulates trafficking in
the early endosomal pathway by causing homotypic fusion of early endosomes
[129].
EPS8, by virtue of its SH3 domain, was found to integrate these two
processes. EPS8 interacts with SOS1 in the Rac pathway. EPS8 also binds to
RN-Tre, a Rab5 GTPase that is regulated by EGFR [130]. RN-Tre comprises
of TrH3 (tre homology domain) domain with two conserved arginine residues,
the catalytic core of their Rab5-GAP activity. RN-Tre over expression inhibits
Rab5-mediated constitutive endocytosis [130] of the transferrin receptor as well
as ligand-dependent internalization of EGFR. However, some researchers have
claimed that upon EGF stimulation RN-Tre undergoes a serine phosphoryla-
tion, which downregulates its GAP activity [9]. EPS8 mediates only ligand
dependent endocytosis of EGFR via binding with RN-Tre. The interesting and
rate limiting point in this process is when both Abi1 and RN-Tre compete to
bind to the EPS8’s SH3 domain which determines the transmission of EGFR
signal either through Rac or through Rab5 [45] [130]. An exquisite balance
between the stoichiometry of all these players creates the right circuitry that
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will lead to successful actin remodeling [130].
In the context of cell migration, an area of our interest, the role of
EPS8 becomes rather complex once the Rac effector JNK is considered. RTK
internalization is critical for its signaling, especially the spatial restriction of
the signal. EPS8 binding to RN-Tre inhibits Rab5 mediated EGFR internal-
ization and trafficking [130] which can alter duration and spatial localization
of signaling [24], [116]. Cell migration is further affected by EPS8’s function
as an actin binding and barbed end capping protein. In summary, depending
upon its engagement in different complexes, EPS8 can mediate cellular RTK
signaling and/or cytoskeletal reorganization [96], [95], [205].
1.5.7 Role of EPS8 in Cancer
EPS8 is a tyrosine kinase substrate that augments RTK-induced mi-
togenic responses [68], [57], [151]. RTKs are typically upregulated in most
cancers including breast cancer. Hence, EPS8 is a potential target in cancer
therapeutics, especially since use of RTK inhibitors in the clinic often leads
to drug resistance [164]. Although cell line based studies indicate a role for
EPS8 in tumorigenesis, clinical data regarding tumor progression, especially
metastasis, are still mostly correlative.
Based on in vitro studies, the p97 isoform of EPS8, by virtue of its PH
domain, was shown to be an oncogenic protein [151]. When over expressed, it
induces cellular transformation in vitro leading to development of orthotopic
tumors in mice (0.5cm diameter tumor in 20-30 wk), in an ERK-dependent
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manner [145]. Conversely, a mutation in the PH domain not only stalled
recruitment of EPS8 to the plasma membrane from its resting perinuclear
localization, but also abrogated ERK activation and cellular transformation
[144]. In another study, EPS8 along with IRSp53 was detected at leading edge
of cancer cells probably increasing their invasive potential [67].
Thus, over-expression or constitutive phosphorylation of endogenous
EPS8 in cancer cell lines is associated with increased mitogenic signaling and
malignant transformation in cells [151]. High EPS8 expression is correlated
with increased motility in pancreatic, and colon cancer cells [145]. Over expres-
sion of EPS8 in squamous carcinoma cells increases proliferation and migration
in vitro and induces a tumorigenic phenotype in a xenograft model [230]. In
contrast, pituitary tumor cells with an endogenously elevated EPS8 expression
level correlated increased proliferation but their migration potential remains
unchanged compared to controls [239]. Additionally, a Comparative Genomic
Hybridization (CGH) array on a panel of breast tumors of various grades,
identified EPS8 as a novel putative oncogene that is over expressed in breast
tumors with 12p13 amplification [245].
To summarize, EPS8 by virtue of its multi-networking capability takes
parts in RTK signaling and trafficking and interacts directly with the actin
cytoskeleton, both as a barbed end capper and as an actin binding protein.
Evidence from various in vitro and a few in vivo studies suggests a potential
role for ESP8 in tumor growth, migration and metastasis. Available data sug-
gest that EPS8 is upregulated in some tumors but its role under physiological
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conditions need to be evaluated.
1.6 Significance of Using Mouse Models in Cancer Re-
search
In the last decade, improved early detection tools and a better under-
standing of the biology of breast cancer, translated clinically into a higher
number of women surviving the disease. However, there is still no effective
cure for metastatic breast cancer. With the development of various preclinical
mouse models and in vitro experimental assays that mimic human disease,
we are slowly dissecting the metastatic cascade. Newer approaches have im-
proved our understanding of tumor-stroma interactions. Synthetic matrices
that mimic the human ECM and can be manipulated to alter tumor cell sig-
naling. Also, sophisticated imaging techniques that allow researchers to track
circulating tumor cells or detect early metastases in host tissue are making the
field of metastasis one of the most dynamic areas of cancer research.
Transgenic mouse models have become indispensable in understanding
the biology of breast cancer. They are critical for validation of genes that pre-
dispose humans to the development of breast cancer. The basic paradigm is to
create mouse strains where tumor suppressor genes are deleted or where onco-
genes are over expressed in order to dissect the signaling pathways involved in
breast cancer.
The long term goal of our laboratory is to study the role of JNK isoforms
in breast cancer. For the projects discussed here, two different mouse models
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were utilized to assess the role of JNK isoforms in mammary cancer metastasis.
Firstly, The Polyoma Virus Middle T antigen transgenic model [27], with the
systemic loss of jnk2 was used to study tumorigenesis and lung metastasis as
discussed in Chapter 3. The second project utilized the 4T1.2 mouse mammary
tumor xenograft model to study the role of JNK1 in promoting lung metastases
in Chapter 4.
The Polyoma Virus Middle T Antigen Model
The potent phenotype-transforming activity of Polymona Middle-T
Antigen (PyVMT) is dependent on its specific binding to tyrosine phosphory-
lated kinases (vSrc and cSrc), and the SH2 domain of PI3K [27]. Therefore, the
two primary signaling pathways stimulated by the Polyoma Middle-T Anti-
gen are the MAPK (via Src) and PI3K-Akt cascades [27]. Pathways affected
by these kinases are also activated by RTKs in human breast cancer. Mam-
mary gland specific expression of PyVMT is achieved by establishing trans-
genic founders that carry the Polyoma Middle-T Antigen under transcrip-
tional control of mouse mammary tumor virus promoter (MMTV) [76]. The
mammary-targeted transgenic expression of PyVMT results in a mouse model
that rapidly develops mammary carcinomas with a reported 100% metastases
to the lung [27]. This model closely correlates with the progression of human
breast cancer disease. Development of tumors is spontaneous and exhibits the
full spectrum of stages of human tumor progression including pre-malignant,
malignant and finally metastatic disease [27]. Moreover, these tumors slowly
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lose the expression of steroid hormone receptors (ER/PR) and beta1-integrin
and gain associated upregulation of ErbB2 and cyclin D1 expression in later
stages of the metastatic disease. The MMTV-PyVMT model is characterized
by short latency, high penetrance and frequent lung metastasis, all occurring
independent of pregnancy status of the animal [27].
The 4T1.2 Mouse Mammary Tumor Cell line and Xenograft Model
The 4T1.2 cell lines is a well characterized invasive murine mammary
carcinoma cell line that serves as an excellent xenograft model. This model
allows the study of metastatic progression of breast cancer in humans. The
4T1.2 is a bone- and lung-tropic sub-clone, derived from a single metastasis
of 4T1 cells. The original tumor was derived from a spontaneously growing
mammary tumor in a Balb/c mouse. The 4T1 and 4T1.2 cell line can grow
easily in immune competent Balb/c mice and provide a unique opportunity
to incorporate the role of immune system in tumor growth and metastasis
studies [135]. When modeling spontaneous metastasis the tumor cells are
injected orthotopically into the number four mammary fat pad of Balb/c mice.
Tumors form at the primary site metastasize to the lung, liver, bone and
brain over a period of 3-6 weeks [135] enabling the study of every step of
the metastatic cascade. In the case of experimental metastasis models, tumor
cells are introduced into the circulation via the lateral tail vein, whereby they
rapidly localize to target organs in a short time span of 1-2 weeks [135].
57
1.7 Outline of the Dissertation
Metastasis is a dynamic and complex process by which cancer cells
spread from one organ or tissue to another. The classical metastatic cascade
is comprised of dissemination of tumors cells from the primary tumors, intrava-
sation into vessels, migration and circulation into lymph or vascular systems,
extravasation and arrest in distant organs. Cells extravasate into tissue by
proteolytic degradation of the ECM and then grow into metastatic foci. The
cancer cell works in tandem with its surrounding stroma during the entire
process of metastasis and stromal cytokines and mitogens regulate by various
signaling pathways in the tumor cell. The overall purpose of my research is
to identify an isoform specific function of JNK in promoting mammary cancer
metastasis.
One such signaling molecule, JNK, can be activated by a variety of
extracellular stimuli such as DNA damage, mitogens and stress. Of particular
interest is understanding how cancer cell interprets JNK activation. JNK
signaling affects one or many of the individual events in the metastasis cascade
such as adhesion, migration, invasion colonization or even angiogenesis. My
current research focuses on identifying the isoforms of JNK that regulates each
step of metastasis.
To distinguish between roles of JNK1 and JNK2 in breast cancer metas-
tasis, I will present my observations in two parts. In Chapter 3, I will discuss
my findings on JNK2, focusing on mechanisms of cell migration in vitro. In
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Chapter 4, I will discuss my results role of JNK1 in mammary cancer metas-
tasis in vivo.
59
Chapter 2
Experimental Designs
2.1 In vitro methods
2.2 Materials
In general, all materials and chemicals were purchased from Sigma
(St. Louis, MO) unless otherwise noted. The small-molecule inhibitors of
JNK include 1,9-pyrazoloanthrone or SP600125 compound (Cat # 420119,
Calbiochem, La Jolla, CA) and JNK Inhibitor VII TAT-TI-JIP153-163 (Cal-
biochem, Cat #420134). The latter, referred henceforth as TAT-JIP is based
on JNK-Interacting Protein 1 (H2N-YGRKKRRQRRR-RPKRPTTLNLF-CH2).
Commercially available human fibronectin (BD Biosciences Cat # 354008),
was used for migration, MatrigelTM (BD Biosciences Cat #356230), and type-
I collagen (PureColTM, Inamed, Fremont, CA) was used for invasion assays.
2.3 Cell culture
Mouse mammary tumor cell lines were created from PyVMTjnk2+/+
and PyVMTjnk2−/− tumors from mice. Tumors were excised using sterile
conditions and minced. The minced tumor mass was digested overnight in
a shaking water bath. Next day the cells were plated in low serum condi-
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tion to remove fibroblasts. The epithelial population was selected over time.
Cells were routinely maintained in DMEM F-12 media (Cat # 10-092-CV,
Cellgro, Mediatech, Herndon, VA), supplemented with 10% heat inactivated
Fetal Bovine Serum (FBS) (Cat # 100-106, Benchmark Gemini Bio-Products,
Sacramento, CA), 10µg/ml insulin (Humulin RTM , Lilly Indianapolis, IN),
5ng/ml EGF (Cat # 100-15, PeproTech Rocky Hill, NJ), 20 units/ml nys-
tatin (Cat# N1638, Sigma St. Louis, MO), 5µg/ml linoleic acid (Cat #
354008 BD BioScience, San Jose, CA), 10 mg/ml penicillin and streptomycin
(10mg/ml) (Cat # 15410, Invitrogen, Carlsbad, CA), and 5µg/ml gentamicin
(Cat# 15750-060, Gibco, Carlsbad, CA). Cells were incubated at 37◦C, in a
humidified incubator with 5% CO2. Serum free medium (SFM) treatments
consisted of DMEM F-12 medium containing 10mM HEPES (pH 7.4), trans-
ferrin (1mg/ml), human fibronectin (1mg/ml 1X Trace Elements (Cat # 349-
020), Biosource, Camarillo, CA), and 10 mg/ml penicillin and streptomycin
(10mg/ml). 4T1.2 cell line was maintained in a 5% CO2 incubator in MEM
(alpha modification) (Gibco/Invitrogen Cat # 32561) containing 10% FBS
and antibiotics (penicillin and streptomycin). Cells were passaged every third
day and maintained mycoplasma free using Mycoplasma Kit (Takara Cat#
6601) periodically. MDA MB 231 cell line, an established human metastatic
breast cancer cell line, was used to supplement data obtained from murine
carcinoma cells. MDA MB 231 cells were cultured in IMEM (Cellgro Mediat-
ech Cat# 10-026-CV) medium without phenol red, with 1% insulin, 10% FBS
and penicillin/streptomycin. For growth factor stimulated experiments and
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zymograms, cells were plated at a density of 2 million cells per 10-cm culture
dishes (BD Biosciences, Lincoln Park, NJ) and allowed to grow overnight. The
following day, after two washes with warm PBS (Phosphate Buffered Saline)
the medium was replaced with SFM. Sixteen to 20 hours later, cells were stim-
ulated with 10% FBS added to SFM. For experiments using small-molecule
inhibitors, cells were pre-incubated with SP600125 (10 µM) or TAT-TI JNK
Inhibitor VII/ JIP (4, 10, 25 µM) for 30 minutes before stimulating with 10%
FBS (in the presence of the inhibitor).
2.4 Immunoblotting
Cells were lysed using either RIPA immunoprecipitation buffer (50 mM
Tris-HCl (pH 7.4), 1% NP-40, 0.25% Na-deoxycholate, 150mM NaCl, 1mM
EDTA) or EB buffer (0.05% NP-40, 20mM Tris HCl (pH 7.6), 0.25M NaCl,
3mM EDTA) depending on location and sensitivity of proteins. When harvest-
ing tumors for protein lysates, a portion of the fresh or snap frozen tumor was
excised on dry ice, using sterile scalpels and homogenized with a motorized
homogenizer (PRO 200, PRO Scientific Inc, CT, USA) until the tumor became
a homogeneous lysate in either RIPA or EB buffer. An additional sonication
(for 2 min at 6) step was added to increase yield. Protein lysates were cleared
by centrifuging at 14xg for 15 minutes. Total protein (60 µg) was separated
using 10% SDS-PAGE and electrophoretically transferred to nitrocellulose for
1 h (100V) at room temperature. Membranes were blocked with TBS (Tris
base, NaCl, pH 7.6) plus 0.05% Tween 20 (TBST) containing 5% nonfat milk
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or 5% BSA (bovine serum albumin) for 1 hour, followed by incubation with
a 1:1000 dilution of specific antibody for overnight or anti-β-tubulin/GAPDH
antibodies in blocking solution at 37◦C for 1 hour. Membranes were later
washed with TBST, and then incubated with a horseradish peroxidase-linked
secondary antibody (Santa Cruz Bio Tech, NJ) at a dilution of 1:2000. Pro-
teins were visualized using the ECL Plus Western Blotting Detection System,
according to the manufacturer’s protocols (Cat # RPN2132, Amersham GE,
UK) using a Phospho-Imager STORM 860 (Amersham Biosciences, Piscat-
away, NJ).
2.5 Immunocytochemistry
Typically, about 4 million cells were plated overnight in 8 well cham-
ber slides with or without fibronectin coating (BD Bio coat cat # 154453).
Next, the cells were rinsed twice with sterile PBS and then serum starved
for 6-10 hours before treatment with complete medium with 10% FBS. At
the time of harvest wells were washed three times in PBS, and fixed for 30
min at room temperature with 4% paraformaldehyde (Cat #T353-500, Fisher
Scientific, NJ, USA) in PBS or with 1:1 acetone /methanol solution at -20C
for 10 min. After fixation, cells were permeabilized with 0.1% Triton X-100/
/PBS for 10 min. Slides were rinsed with PBS, cells and then blocked with
10% normal goat serum (Cat # U 0512, Vector Laboratories, CA) in PBS
at 37◦C for 1 hr. Primary antibody (EPS8, Cat# 610144, BD Biosciences)
was diluted in 0.1% Triton X-100/ /PBS/10% normal goat serum and applied
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onto slides overnight at 4◦C. The next day, slides were washed three times
for 10 min each and then incubated with a FITC or Texas Red conjugated
mouse or rabbit secondary antibody (Cat# A21202, Molecular probes) for 1
h at room temperature. Finally, slides were washed three times with PBS (10
min each), and then mounted on a glass slide with Vectashield DAPI mount-
ing reagent (Molecular Probes, Eugene, OR). Fluorescent signal was detected
using a cooled charge-coupled device (CCD) camera mounted on a Nikon Di-
aphot 300 inverted microscope.
2.6 Cell migration assay
Cell migration was measured using a modified Boyden chamber where
two chambers are separated by a filter through which cells migrate through
8 um pores (Cat # 353097, BD, Falcon). Briefly, sub-confluent cells were
washed, trypsinized to obtain single-cell suspension, and suspended in Hanks
Balanced Salt Solution (HBSS) medium containing 0.1 % bovine serum albu-
min. In the standard assay, 0.5 million cells were plated on fibronectin-coated
(10µg/ml) polycarbonate filters and placed in the upper compartment of the
Transwell chamber. Lower chambers were filled with 0.7 ml of 1% FBS contain-
ing growth medium. Cells were allowed to migrate in a humidified incubator
with 5% CO2 at 37
◦C for 8h. Filters were then removed and the upper side
was wiped off with a cotton applicator to remove non-migrated cells. Migrated
cells were fixed with 4% paraformaldehyde, stained with 0.5% Crystal Violet
(Fisher, Middletown, VA) and quantified by counting four randomly chosen
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fields (at 10x objective). Where indicated, cells were pretreated for 30 min
with varying concentrations of TAT-JIP prior to migration assays.
2.7 Cell invasion assay
Tumor cell invasion was assessed in vitro by assessing tumor cell’s
ability to digest and migrate through a type-I collagen matrix layer towards
medium with 10% serum. For PyVMTjnk2−/− and PyVMTjnk2+/+ cells
collagen was used as the invasion matrix. Collagen was neutralized by mixing
on ice, 0.5ml 1X type-1 Collagen (PureCoTM, Inamed at 2.9 mg/ml and pH
2), 62.5µl 10X sterile PBS, and 62.5 l 0.1M NaOH. The pH was adjusted to 7.0
using 0.1N HCl. The commercially available type-I collagen stock was diluted
from 3mg/ml (1X) to 0.3X. The final pH was adjusted to 6 and 7. Inserts were
coated with 30 l of 0.3X collagen at pH 6 or pH 7 and allowed to polymerize in
a 37◦C oven until the collagen turned opaque (approximately 2 hrs). Briefly,
sub-confluent cell cultures were washed, trypsinized, and suspended into a
single-cell suspension using HBSS medium containing 0.1 % bovine serum al-
bumin. In the standard assay, 0.03 million cells were plated on collagen-coated
polycarbonate filters and placed in the upper compartment of the Transwell
chamber. Lower chambers were filled with 0.7 ml of 10% FBS containing
growth media. Cells were allowed to invade in a humidified incubator with
5% CO2 at 37
◦C for 24h. Filters were then removed, and their upper chamber
was wiped off with a cotton applicator to remove non-migrated cells. Migrated
cells were fixed with 4% paraformaldehyde, stained with 0.5% Crystal Violet
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(Fisher, Middletown, VA) and quantified by counting four randomly chosen
fields (10). Where indicated, cells were pretreated for 30 min with varying
concentrations of TAT-JIP prior to the invasion assays. For in vitro invasion
assay with 4T1.2 clones (4T1.2 GIPZ and 4T1.2 shJNK2), MatrigelTM (Cat
# 356230, BD Bioscience, San Jose, CA), a commercially available basement
membrane matrix composed of collagens, laminins and fibronectin was used.
MatrigelTM provides a biologically active basement membrane for in vitro in-
vasion assays. The growth factor reduced stock of MatrigelTM was diluted 1:5
with 1X HBSS and 30l of diluted MatrigelTM was used to coat the 8µm poly-
carbonate filters of the Transwell chamber. Lower chambers were filled with
0.7 ml of 10% FBS containing α MEM growth media. Cells were incubated
in a humidified incubator with 5% CO2 at 37
◦C for 15h. Filters were then
removed, and their upper side was wiped off with a cotton applicator to re-
move non-migrated cells. Migrated cells were fixed with 4% paraformaldehyde,
stained with 0.5% Crystal Violet (Fisher, Middletown, VA) and quantified by
counting four randomly chosen fields (10x).
2.8 Cell viability assay using MTT
Yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide, a tetrazole) is reduced to insoluble purple formazan by enzyme reductase
in active cells, reflecting viability of cells. PYVMTjnk2+/+, PYVMTjnk2-/-
, PYVMTjnk2+/+ sheps8, PYVMTjnk2+/+ GIPZ, PYVMTjnk2-/- GIPZ,
PYVMTjnk2-/- shEPS8, and 4T1.2 psm2, 4T1.2 shJNK1. 0.02 million cells
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were plated into each well of a 12-well plate in 1ml of 10% FBS containing
media or 1% FBS as specified. Each day for four days, 100 µl of MTT solution
(5 mg/ml in PBS, Sigma Cat # M2128-1G) was added to each well. Cells
were incubated at 37◦C for 4 h. MTT crystals were then solubilized in 2000
µl of DMSO. Since responses were linear with time, differences in treatment
were compared using a two-way analysis of variance (ANOVA). Absorbance
was read at 550 nm.
2.9 EGF internalization assay
Approximately 0.03 million cells were plated in 8 well chamber slides
overnight in complete media in 5% CO2 and 37
◦C. After two PBS rinses cells
were grown in SFM for 10 hours. At the end of serum starvation slides were
kept on ice for 10 minutes to stall receptor activity. 100ng/ml or 10ng/ml FITC
488 conjugated EGF or Texas Red-EGF (Molecular Probes Cat # E13345 and
Cat # E3480) was added to the cells to stimulate/ internalize the EGFR and
immediately transferred to 37◦C incubator. After specified time points slides
were taken out and kept on ice. The zero hour time point was added on ice.
Acid stripping of excess membrane bound ligand was performed by using ice-
cold 0.2 mM acetic acid, 0.5 mM NaCl (pH 2.5) for 2 x 2 minutes and 1 x 1
minute, followed by neutralization in ice-cold HBSS (CellGro). EGF internal-
ization was assessed qualitatively by visualization of FITC/ rhodamine-EGF
signal in jnk2 expressing cells and cells expressing shEPS8, or with jnk2-/-
cells.
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2.10 Scratch wound assay
Briefly, 1 million cells were plated over-night in 6-well plates so that a
confluent monolayer in formed. The next day, the cell monolayer was scraped
in a straight line to create a ”scratch” using a sterile p200 pipette tip. The
debris was removed, and the edges of the scratch were smoothened by gently
washing the cells with 1ml of growth media then replacing it with 2ml of 1%
serum containing assay media. To obtain the same field during the image
acquisition, markings were placed on the plate bottom with an ultra fine tip
marker. For wound assays with ERK and PI3K inhibitors, the above protocol
was followed except after wounding the replacement media was supplemented
with various concentrations of the inhibitors, as indicated in figure legends.
For the RN-Tre over expression studies, 0.5 million cells were plated
overnight and transfected using vector DNA and Lipofectamine 2000 reagent
(Invitrogen, CA, USA) according to the manufacturer’s protocol. Twenty-four
hours after transfection, a scratch wound was created. Cells were cultured
for 12 hr and then images captured. Changes in the open wound widths
were measured by comparing the distance measured at the time of wounding
vs. at the time of harvest. Transiently transfected cells were later lysed and
immunoblotted to determine the expression of the vector.
2.11 Rac activity assay
Rac activation was evaluated using the GST-CRIB pull down assay. In
brief, a subconfluent 10 cm2 dishes of monolayer cells were serum starved for
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10 hours and then stimulated with 1% or 10% FBS containing growth media.
Cells were lysed on ice in GST-FISH lysis buffer (50 mM Tris-HCl, pH 7.4,
1% NP-40, 100 mM NaCl, 10% glycerol, 5 mM MgCl2, 1 g/ml leupeptin, 1
mM PMSF) at the indicated time points. The lysates were centrifuged at
15 x g for 15 min at 4◦C, and the resulting supernatants were incubated for
30 min at 4◦C with GST-PAK-CRIB substrate immobilized on glutathione
sepharose beads (Amersham Cat # 17-0756-01). Beads and lysates were in-
cubated for 3 hours at 4◦C. After binding of activated Rac to its substrate
the beads were washed 3x times with lysis buffer. Activated Rac was eluted
using 10mM reduced glutathione (Cat # 7018-8 ). Samples were then mixed
with 4x mercaptoethanol containing sample loading buffer and analyzed on an
SDS-PAGE. Samples were transferred and probed with anti Rac1B antibody
(Millipore Cat # 09-271).
2.12 Viral transductions
2.12.1 Retroviral transduction
The retroviral non-silencing empty vector (psm2) (Open Biosystems
Cat # RHS1701) and shJNK1 (Open Biosystems Cat # 170501) constructs
along with VSVG viral coat protein encoding constructs were transfected into
GP293 Phoenix cells by a calcium phosphate precipitation method. About 18
h post-transfection, GP293 cells were washed once with PBS, and the media
was changed to complete growth medium (DMEM, 10% FBS, glutamine, peni-
cillin/streptomycin). Approximately 48 h post-transfection, the supernatant
69
was harvested, passed through a 0.45µm filter to remove cellular debris, and
mixed with Polybrene (8µg/ml). In a separate culture dish, 0.2 million 4T1.2
cells were infected with a 1:1 mixture of viral-containing supernatant and com-
plete growth medium. Aspiration and infection were repeated twice every 24
h. To generate stable pools of shRNA expessing cell lines, the cells were placed
in complete growth media supplemented with puromycin (4µg/ml) for 1 week.
Single surviving clones were selected out and expanded thereby avoiding clonal
variability.
2.12.2 Lentiviral transduction
The lentiviral GFP tagged non-silencing empty vector (GIPZ Open
Biosystems Cat # RHS4346) and corresponding shJNK2 or shEPS8 (Open
Biosystems Acc # NM 016961 or NM 0045 for shEPS8) constructs along with
three constructs P1, P2 and P3 (encoding for viral proteins gag, pol and env)
constructs were transfected at a 1:2 (target gene vs. viral coat proteins) into
commercially available GP293 packaging cells (Clontech Cat # 631530) using
Lipofectamine 2000 (Invitrogen, CA, USA) according to manufacturer’s pro-
tocols. About 18 h post-transfection, cells were washed once with PBS, and
the media was changed to complete growth medium (DMEM, 10% FBS, glu-
tamine, penicillin/streptomycin). Approximately 48 h post-transfection, the
supernatant from transfected Phoenix cells was harvested, passed through a
0.45µm filter to remove cellular debris, and mixed with Polybrene (8µg/ml).
1 million cells (jnk2+/+, PyVMTjnk2-/-, or 4T1.2) were infected with the
70
viral-containing supernatant and complete growth medium. Aspiration and
infection was repeated twice every 24 h. To generate stable pools of trans-
fected cell lines, the cells were placed in complete growth media supplemented
with puromycin (2.5µg/ml for PyVMT cells) for 1 week. GFP expression was
qualitatively analyzed for efficiency of transduction.
2.13 Protein concentration determination
Protein concentrations of cell extracts were determined by the method
of Lowry using bovine serum albumin as a standard. Reagents were purchased
from Bio-Rad (Solution A Cat # 210003876, Solution B Cat # 210004806 and
Solution S Cat # 210005254)
2.14 Real-Time PCR analysis
Total RNA was isolated from PyVMTjnk2+/+ and PyVMTjnk2-/-cells
using the QIAGEN RNAEasy RNA isolation kit (Valencia, CA). First-strand
complementary c-DNA was made using 1-2µg total RNA in the presence of
Superscript II reverse transcriptase and oligo-dT primer (both from Life Tech-
nologies, Carlsbad, CA). PCR reaction was performed using real-time-PCR
method as indicated. PCR products of Jnk1 1, Jnk1 2, Jnk1α1, Jnk2α1, and
Jnk21and Jnk3α and Jnk3β were amplified using the primers published by
Dreskin et al., 200131. Real-time was performed on a Stratagene Mx3005P
thermocycler using the Brilliant SYBR green PCR master mix (Cat# 600548;
Stratagene, La Jolla, CA). The PCR conditions included a 10-min, 95◦C ac-
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tivating cycle, followed by 45 amplification cycles of 95◦C for 30 sec, 60◦C for
1 min, and 72◦C for 30 sec. To control for mRNA variation amongst samples,
GAPDH controls were used for each sample. A baseline calibrator was run
for each c-DNA set used and individual samples were run in duplicate. The
expression level for each sample was normalized to a single calibrator sample
so that the numerical values from the samples at either temperature can be
directly compared.
Table 2.1: Real Time PCR Primers
Primer Primer Sequence jnk Isoforms
Forward 5′ GAG AAA TGG TTT GCC ACA3′ jnk1b1
Forward 5′ GAG AAA TGG TTT GCC ACA3′ jnk1b1
Reverse 5′ ACT GCT GCA CCT GTG CTA3′
Forward 5′ GGAGAAATGATCAAAGG3′ jnk1a1
Reverse 5′ACTGCTGCACCTAAAGGA3′
Forward 5′GAGAGCTGGTGAAAGGT3′ jnk2b1
Reverse 5′TTACTGCTGCATCTGTGC3′
Forward 5′GAAATGGTCCTCCATAA3′ jnk2a1
Reverse 5′ACTGCTGCATCTGAAGGC3′
Forward 5′GCCTTCTCCTTCAGC3′ jnk3a1
Reverse 5′AGGCAGGCGGCTAGTCAC3′
Forward 5′GCCTTCTCCTTCAGG3′ jnk3a2
Reverse 5′AGGCAGGCGGCTAGTCAC3′
2.15 In vivo methods
2.15.1 Animal studies
All studies used Balb/c mice housed and maintained in the Animal
Resource Center (ARC) at the University of Texas at Austin. Mice were kept
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on a 12-hour light/dark cycle with access to chow (Picolab 20, PMI Nutrition
International) and water. All experiments were performed as per approved
IACUC protocols. PyVMTjnk2-/- transgenic Balb/c mice were generated by
breeding jnk2-/- mice to PyVMT transgenic mice. For the 4T1.2 studies, wild-
type virgin Balb/c mice, both male and female, aged between 6-8 weeks were
injected with tumor cells as indicated in each experiment.
2.15.2 Orthotopic injection of 4T1.2 murine mammary carcinoma
cells
Animals were anesthetized using 2-2-2 Tribromoethanol (20mg/ml stock
solution in normal saline) at a dose of 04.-0.75 mg/gm ( 0.4-0.6µl) and 105
viable 4T1.2 cells expressing shScr or shJNK1 in 50µl volume were orthotopi-
cally injected into the fourth mammary fat pad through a small incision. The
wound was stapled post injection. Tumors were palpable 10-14 days after in-
jection. Primary tumor size was measured thrice weekly using calipers. Once
tumors reached 1cm3 the mice were euthanized and the final tumor weight was
measured. Portions of the tumors were flash frozen in liquid nitrogen or fixed
overnight in 4% paraformaldehyde. To visibly count spontaneous lung metas-
tasis from orthotopic tumors, we perfused the lungs with 2 mL of India ink.
Lungs tumor burden was quantified by manual counting the white metastatic
nodules. We also collected and stored a few lung samples in formalin for his-
tochemical analysis. Other organs were studied closely post mortem for any
signs of metastases
73
2.15.3 Lateral tail-vein injection of 4T1.2 murine mammary carci-
noma cells
Intravenous injection of tumor cells via the lateral tail vein is used as
an experimental metastasis model. Using this approach, tumor cells bypass
local invasion as a necessary step of endogenous tumors during metastasis.
Circulating tumor cells get trapped in the fine capillaries of the enriched lung
microenvironment where they extravasate and colonize forming visible metas-
tases. We injected 0.05 million 4T1.2 shScr or shJNK1 expressing cells (in
100µl) into the lateral tail vein of 6-8 week old male and female Balb/c mice.
Mice were observed daily for signs of morbidity such as labored breathing and
ruffling of the skin. Fifteen days after injection, mice were sacrificed and their
lungs were harvested. Again, India ink was injected through the trachea to
perfuse the inner airspaces and inflate the lung lobes. Lungs were then excised
and placed in Fekete’s destaining/fixing solution (100ml of 70% ethanol, 10ml
of 4% paraformaldehyde, 5ml glacial acetic acid) for overnight at 4◦C. The
next day the stained lungs were placed in 70% ethanol for storage. Analysis
was performed by separating the lobes to visualize all surfaces of each lobe.
During counting, all the lobes were included and metastases were categorized
according to their average sizes into three groups. Representative lungs were
also paraffin-embedded and processed for histological analysis.
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2.15.4 Micro-array
First, total RNA was extracted from snap frozen tumors obtained from
orthotopic injection of 4T1.2 shScr and shJNK1 using TRIzol TM Reagent
(monophasic solutions of phenol and guanidine isothiocyanatethat denatures
protein, Invitrogen Cat# 15596-026). Chloroform was used to partition RNA
into an aqueous supernatant for separation. RNA quality and purity was
checked by analyzing the RNA is a denaturing agarose gels and also checking
260/280 and 260/230 ratios.
The first step of sample preparation for microarray analysis involved
reverse transcription of RNA to cDNA using from the Invitrogen Super Script
TM double stranded cDNA synthesis kit. Essentially, first strand was created
by superscript reverse transcriptase II (Invitrogen Cat #18064-014) followed
by synthesis of the complimentary strand of the cDNA using a combination
of DNA ligase, DNA polymerase, RNase H and T4 DNA polymerase. The
double stranded cDNA was then cleaned using RNase A, and the cDNA was
precipitated using 7.5M ammonium acetate with 5mg/ml glycogen. In the
second step samples were labeled and hybridized to a NimbleGen 385K-4plex
mouse array (Roche, WI USA). Subsequently the chips were washed, dried
and scanned. Data were extracted from the scanned image and analyzed for
gene expression levels.
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2.16 Statistical analysis
Results are presented as mean SE. Results were evaluated using ANOVA
followed by non-parametric, post-hoc Student’s t-test to identify differences
between specific variables. Differences between means yielding P values of =
0.05 were considered significant. Statistical analysis was done using GraphPad
Prism version 4 (GraphPad software Inc., CA, USA).
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Chapter 3
Role of JNK2 in Cell Migration
Our laboratory has been studying JNK signaling in breast cancer,
specifically in response to insulin like growth factor (IGF) for several years
[147]. My interest in JNK protein stems from the fact that critical media-
tors of cell migration and invasion such as Rac, FAK, and Src activate JNK
in response to growth factors [7]. Recently, JNK activation was associated
with EGF-induced cell migration [8], [38]. Moreover, inhibition of JNK or
its upstream kinase MKK4 activity through expression of dominant negative
genes or chemical inhibition, reduces cell migration [242]. Biochemically, sev-
eral JNK substrates such as IRS-1, p66Shc and paxillin are closely associated
with cell migration [17] [91]. Key evidence was provided by Huang et al.,
who showed using recombinant proteins that JNK phosphorylates the focal
adhesion adaptor protein,paxillin on Ser178 (in vitro and in vivo) to directly
facilitate cell migration. Since JNK is detected at focal adhesions, some spec-
ulate that JNK-paxillin association degrades the focal adhesion assembly at
the migrating edge of the cell or interferes with the binding of other essential
partners of paxillin, facilitating cell movement [87].
Our laboratory’s preliminary observations, based on microarray analy-
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sis with have identified EPS 8 as a candidate gene for mediating JNK2 depen-
dent effects on cytoskeleton. These data showed that loss of jnk2 significantly
increases the expression of EPS8 in the PyVMT murine mammary carcinoma
cells. As elaborated in the introduction, EPS8 has profound influence on actin
cytoskeleton and cell migration by virtue of its association with EGFR and
F-actin [205].
Based on these evidences my hypothesis is that JNK2 increases tu-
mor cell migration by regulating the expression and localization EPS8 which
directly alters EGFR signaing and trafficking.
To test my hypothesis, I propose the following specific aims:
Specific Aim 1: Determine if JNK2 increases mammary tumor cell
migration in EPS8 dependent manner.
Specific Aim 2: Determine the mechanism(s) by which JNK2-EPS8
interaction regulates migration.
3.1 The Role of JNK2 in Cell Migration in a PyVMT
Mammary Tumor Model
Rationale and Significance: Migration is an intracellular signaling driven
chemotactic event where direction of migration is governed by growth factor
gradients. Growth factors activate specific JNK isoforms downstream of EGFR
signaling pathway [8]. For example, JNK2 was preferentially activated by EGF
in A549 cells and expression of antisense JNK2 inhibited proliferation in the
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same [8]. JNK2 (p55) is also the predominant isoform in many cancers in-
cluding glial tumors [222]. Therefore, we evaluated the role of JNK2 in cell
migration. The MMTV-PyVMT for mammary tumorigenesis was used for our
studies.
3.1.1 JNK2 Modulates EPS8 Expression in PyVMT Mammary Tu-
mors
Our microarray studies demonstrated that EPS8 RNA expression in
the PyVMTjnk2-/- mammary tumors is 3.9-7.8 fold higher than in tumors
from the wild-type counterparts (PyVMT jnk2+/+). Using real-time PCR,
a four-fold increase in EPS8 mRNA expression in the PyVMTjnk2-/- tumors
verified the microarray results (Fig. 3.1A). The endogenous EPS8 protein level
was correspondingly higher in the PyVMTjnk2-/- tumors (Fig. 3.1B).
Two cell lines (PyVMTjnk2+/+; PyVMTjnk2-/-) were established from
a pair of PyVMT wild type and jnk2 knockout mammary tumors using stan-
dard methods to facilitate biochemical studies. Using these cell lines we ex-
amined if deletion of jnk2 induced a compensatory increase in jnk1 or jnk3
expression. Quantitative analysis of jnk1 and jnk3 mRNA showed no signif-
icant differences between the two cell lines (Fig. 3.1C). In contrast, jnk2α1
and jnk2β1 messages(normalized to GAPDH) were 50- and 150-fold higher,
respectively, in the PyVMTjnk2+/+ cells compared to their PyVMTjnk2-/-
counterparts. Analyzing JNK protein expression using a JNK1 specific anti-
body (recognizes p55 and p46 isoforms) showed that both cell lines expressed
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Figure 3.1: Loss of jnk2 increases EPS8 expression.
A). PyVMTjnk2+/+ and PyVMT/jnk2-/- mouse mammary tumors were snap frozen and
RNA isolated and cDNA reverse-transcribed as described in Chapter 2. qPCR reactions
were performed using eps8 and gapdh primers. A minimum of four samples per genotype
was used. B). PyVMTjnk2+/+ and PyVMTjnk2-/- mouse mammary tumors were snap
frozen and homogenized in cell lysis buffer. Total protein from tumor lysates was separated
by SDS PAGE and then transferred to nitrocellulose. Membranes were probed using EPS8
primary antibody, and protein expression was detected as described in Chapter 2. C).
qPCR reactions were performed using jnk1, jnk2, jnk3 and gapdh primers. A minimum of
four samples per genotype were analyzed. D). PyVMTjnk2+/+ and PyVMTjnk2-/- mouse
mammary cell lines were lysed. Total protein from tumor lysates was separated by SDS
PAGE and then transferred to nitrocellulose. Membranes were probed using JNK1, JNK2
or GAPDH primary antibodies. E). Subconfluent PyVMTjnk2+/+ and PyVMTjnk2-/-
cells were serum starved overnight before stimulating with 10% FBS for 60 mins. The
cytosolic and membrane fractions were separated using lysis buffer with and without
Triton. Actin primary antibody was used to evaluate equal loading amongst samples.
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Figure 3.2: Loss of JNK2 increases EPS8 expression in normal mammary
gland.
The 4th mammary gland from 5 week old virgin Balb/c mice were fixed in paraformaldehyde
and embedded in paraffin. Consecutive 5µm sections were cut and stained by indirect
avidin-biotin immunoperoxidase using EPS8 specific primary antibody and hematoxylin
counterstaining. Intense positive immune reaction (brown) was evidenced in the TEBs
of both sets of mammary glands epithelium cells (original magnification 40X) A). TEB
from a representative jnk2+/+ gland and B). TEB from a representative jnk2-/- gland.
C). Quantification of EPS8 positive cells was performed by counting all the positive cells
in each TEB (n=9) and represented as % of total epithelial cells in the duct(*p=0.0168,
two-sided Student’s t-test).
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similar levels of JNK1α1/2 (p55) and JNK1β2 (p46) proteins (Fig. 3.1D).
Next, a JNK2 specific antibody that detects both the p55 (JNK2α1 and α2)
and p46 (JNK2β1 and β2) was used to analyze JNK2 expression. As an-
ticipated the p55 and p46 JNK2 isoforms were expressed exclusively in the
PyVMTjnk2+/+ lysates (Fig. 3.1D).
EPS8 expression was evaluated in membrane (Triton insoluble fraction)
and cytosolic (Triton soluble fraction) compartments using an antibody against
total EPS8. Overall, EPS8 expression was higher in the PyVMTjnk2-/- cells.
In both cell lines, the Triton soluble fraction had a higher concentration of
EPS8. Castagnino and colleagues (1995) have previously shown that EPS8
binds to juxtamembrane domain of EGFR, so it was expected that we would
see a higher concentration of EPS8 in the triton soluble fraction (Fig. 3.1E)
[28].
Together, these data show that deletion of jnk2 increases endogenous
expression of EPS8 protein in the PyVMT mammary tumor model but does
not affect other JNK isoforms. Moreover, this inverse correlation between
JNK2 and EPS8 was not restricted to cancer models. In an unrelated exper-
iment, immunohistochemical analysis of 5 week old virgin mammary glands
from Balb/c mice also showed significant increase in EPS8 expression (p=0.016)
in the ducts and terminal end buds of jnk2-/- glands. This suggests that JNK2
and EPS8 may have a functional inverse correlation during mammary ductal
development as well as tumorigenesis. (Fig. 3.2A–C).
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3.1.2 Loss of JNK2 Inhibits Directional Cell Migration
RTKs such as EGFR and PDGFR regulate cell proliferation and mi-
gration [190]. Both JNK and EPS8 are downstream signaling mediators of
EGFR signaling. It seems plausible that the loss of JNK2 and associated up-
regulation of EPS8 affects cell proliferation. In fact, in vivo studies with the
PyVMTjnk2-/- tumors showed slightly higher growth rate and statistically
significant increase in tumor multiplicity (O Neal et.al.unpublished data).
To determine differences in proliferation rates between the cell lines,
a MTT-based viability assay was performed. Using 10% FBS and 1% FBS
containing growth media, the cell lines did not show any significant differences
in cell proliferation (data not shown) leading us to postulate that the impact
of EPS8 maybe on metastasis.
Accordingly, the migration potential of PyVMTjnk2+/+ and PyVMTjnk2-
/- cells were examined using a modified Boyden chamber based assay, with
low serum growth media (1% FBS) to limit proliferation. Remarkably, the
migration potential of PyVMTjnk2+/+ cells was five-fold higher than the
PyVMTjnk2-/- cells (untreated groups, Fig. 3.3A) in multiple experiments.
Subsequently, when other JNK isoforms were inhibited by pre-incubating cells
with increasing concentrations of a commercial pan-JNK inhibitor, TAT-JIP,
only migration of PyVMTjnk2+/+ cells was reduced in a concentration de-
pendent fashion (Fig. 3.3A). At the lowest concentration (4µM), TAT-JIP in-
hibited PyVMTjnk2+/+ cell migration by 50%; and at 10µM, migration was
inhibited by 80%. In contrast, the limited cell migration in PyVMTjnk2-/-
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Figure 3.3: JNK2 mediates cancer cell migration.
A). Equal number of PyVMTjnk2+/+ and PyVMTjnk2-/- cells were pre-treated
with various concentration of TAT-JIP for 30 mins before they were plated in duplicates
in the upper chambers in serum free media with 1% FBS in the lower chamber. After 8
hrs, the number of migrated cells was determined by counting four fields per insert. This
is a representative of 5 independent experiments. B). GFP or GFP JNK2α (p54) was
introduced by retroviral transduction in PyVMTjnk2-/- cells to create stable clones, which
were assayed as above. This is a representative of 3 independent experiments. (*p=0.0302,
two-sided Student’s t-test). C).Uniform scratch wounds were made on a compact monolayer
of PyVMTjnk2-/-GFP or PyVMTjnk2-/-GFPJNK2 cells in 1% FBS and wound healing
was measured after 20 hrs. The distance migrated by cells was calculated as the percentage
of wound closure from time 0 to 20 hrs post scratch. This is representative of 2 independent
experiments.
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Figure 3.4: JNK mediates cancer cell migration in MDA-MB231 cells.
A). 0.005 million PyVMTjnk2+/+ and #3625 PyVMTjnk2-/- (a second tumor de-
rived cell line) cells were plated in the upper chambers of 8m inserts in serum free media
in duplicates. 1% FBS was the chemoattractant in the lower chamber. Cell migration
was measured after 8 hrs as described in the 3.3 section. For each well, four fields were
counted. This is a representative of at least 2 independent experiments. B). 0.0075 million
MDA-MB- 231 cell, pretreated for 30 mins with indicated concentrations of TAT-JIP VII
were used in a Boyden Chamber migration assay. Four individual fields were counted per
insert. The 25uM TAT-JIP treatment showed significantly reduced migration (**p=0.016
M JIP two-sided Student’s t-test). This is a representative of 2 independent experiments.
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cells remained unaltered with TAT-JIP treatment (Fig. 3.3A).
To confirm that expression of JNK2 promotes cell migration, we used
the strategy of re-expressing JNK2 in the PyVMTjnk2-/- cells. Re-expression
of JNK2α (PyVMTjnk2-/-GFP-jnk2α) successfully rescued the migration ca-
pacity of these cells (Fig. 3.3B) in both Boyden chamber assays and wound
healing assays (Fig. 3.3C).
For additional validation, a second PyVMTjnk2-/- tumor was converted
into a cell line (#3625 PyVMTjnk2-/-) which tested similarly for reduced cell
migration when compared to the PyVMTjnk2+/+ control (Fig. 3.4A).
To establish the relevance of our data in a human breast cancer model,
MDA-MB 231 cells were treated with various concentrations of TAT-JIP and
these experiments showed dose dependent reduction in migration which was
significant at a 25µM concentration (Fig. 3.4B).
3.1.3 JNK2 Modulates Cell Migration in the 4T1.2 Mammary Car-
cinoma Model
To ensure that our observations were not unique and restricted to the
PyVMT model, we stably infected 4T1.2 murine mammary cancer cells with
shRNA targeted towards JNK2. The 4T1.2 is a highly metastatic cell line
originating from a spontaneous mammary carcinoma in a Balb/c mouse and
represents an excellent model for metastatic breast cancer [135]. Infection
of 4T1.2 cells with lentiviral shJNK2 resulted in an 88% reduction in JNK2
protein expression (Fig. 3.5A). Importantly, JNK2 knockdown led to a con-
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Figure 3.5: shJNK2 increases EPS8 expression and reduces migration in
4T1.2 mammary tumor cells.
A). 4T1.2 mouse mammary tumor cells transduced with shJNK2 or non silencing
vector expressing (GIPZ) lentiviruses showing reduced levels of JNK2 p46/p54 and
concomitant increase in EPS8 expression. GAPDH was used as loading controls. B).
Quantification of A. C). Boyden Chamber based migration assay with GIPZ and shJNK2
expressing 4T1.2 cells performed according to methods described earlier. (**p=0.002,
two-sided Student’s t-test). Representation of 2 independent experiments. Rac-1 activity
was measured in serum (10% FBS for 60 min) stimulated 4T1.2GIPZ and shJNK2 cells
using GST-PAK-CRIB as substrate.
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comitant increase in endogenous EPS8 protein, consistent with our previous
observations in the PyVMT model (Fig. 3.5A). Further, the reduction in JNK2
expression led to a three-fold decrease in cell migration compared to the non-
silencing GIPZ vector controls (Fig. 3.5C) [135]. Scratch wound assays with
4T1.2shjnk2 clones reconfirmed the necessity of JNK2 in mediating cell mi-
gration (data not shown).
Serum stimulation activates small G protein Ras, which, in turn, ac-
tivates downstream Rac1 [200]. Activated Rac interacts with its cytosolic
substrate PAK-1 and translocates to membrane ruffles in migrating cells [79].
Consistent with the decreased migration phenotype, Rac activity was reduced
in the 4T1.2shJNK2 cells, suggesting inefficient Ras-Rac signaling in absence
of JNK2 (Fig. 3.5D).
Taken together, the data establish JNK2 as a critical mediator of mam-
mary cancer cell migration, although its role in proliferation may be less ob-
vious. Loss of JNK2 increases protein expression of EGFR substrate, EPS8
protein in mammary tumors.
3.2 EPS8 is the Key Mediator of JNK2 Dependent Cell
Migration
Rationale and Significance: Recently, various new cytoplasmic targets
of JNK have emerged and some of these play a key role in actin cytoskeletal
reorganization and migration. Signaling cross-talk or changes in protein ex-
pression due to jnk2 knockout may alter important ‘cell-migration’ regulating
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kinases down stream of RTK [204].
EPS8, which is downstream of EGFR plays an important role in regu-
lating migration machinery both at the RTK signaling level and at the actin
cytoskeleton level. Based on the correlation between JNK2 and EPS8, we eval-
uated the role of EPS8 in cell migration. The physiological role of EPS8 in cell
migration is correlative and not well characterized. EPS8 overexpression was
shown to cause an increase in proliferation, and EPS8 inhibition by siRNA
reduced tumor growth [239], [173]. However, there was no strong evidence
regarding cell migration in most studies. Therefore, the role of endogenous
EPS8 in cell migration is yet to be determined accurately.
3.2.1 EPS8 Negatively Regulates Cell Migration in the Absence of
JNK2
Using EPS8 targeted lentiviral short hairpin RNA (shRNA), two sta-
ble clones were generated from the PyVMTjnk2-/- cells with 40% (clone 1)
and 60 % (clone2) reduction in EPS8 expression (Fig. 3.6A). Interestingly,
the clone with maximal reduction in EPS8 expression had a two-fold increase
in cell migration in a Boyden Chamber assay, while the clone with less effi-
cient knock-down had modest 1.4-fold increase in migration compared to the
non-silencing vector (PyVMTjnk2-/-GIPZ) expressing controls (Fig. 3.6B).
The Boyden chamber assay was again validated using the scratch wound as-
say. Indeed, the PyVMTjnk2-/-shEPS8 (clone2), henceforth designated as
PyVMTjnk2-/-shEPS8, consistently covered greater distances in the plate to
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Figure 3.6: Expression of shEPS8 in PyVMT/jnk2-/- cells increases cell
migration.
A). PyVMTjnk2-/- mouse mammary tumor cells were transduced with shEPS8 or
GIPZ non silencing expressing lentiviruses (GIPZ). EPS8 expression was normalized to
individual GAPDH loading controls, and then compared to nonsilencing (GIPZ) expressing
cells. B). GIPZ and shEPS8 expressing cells were assayed in a Boyden Chamber migration
assay. (**p=0.0023, ***p=0.0002; two-sided Student’s t-test). C). Uniform scratch wounds
were made on a compact monolayer of PyVMTjnk2-/-GIPZ or PyVMTjnk2-/-shEPS8 cells
in 1% FBS and wound healing was measured after 20 hrs. The distance migrated by cells
was calculated as the % of wound closure from time 0 to 20 hrs post scratch. This is a
representative of 2 independent experiments.
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close the wounds more rapidly than their GIPZ counterparts (Fig. 3.6C). Thus,
these results show that in the absence of JNK2, EPS8 levels increase, which
inhibits cell migration demonstrating that the abiity of JNK2 to stimulate
migration depends on downregulation of EPS8.
3.3 The Molecular Mechanism of JNK2 Mediated Cell
Migration
Rationale and Significance: Cell migration is a cyclical process com-
prised of four sequential steps namely: polarization, protrusion, traction and
retraction. Cells reorganize their cytoskeleton to polarize into a dorsal edge
and a leading edge. Extrapolating the role of JNK in ‘epithelial planar polar-
ity’ in Drosophila [14], one can hypothesize that JNK2 plays an important role
in polarization of the migrating cell. At the leading edge, the expanding lamel-
lopodia protrudes against the plasma membrane resulting in the formation of
ruffles, which are areas of high actin dynamics and earliest visual hallmarks of
a migrating cell. Differential rate of endocytosis of membrane receptors and
integrins at the leading edge vs. the trailing accounts for the polarization of
the cell.
The small GTP binding protein Rac, regulates membrane ruffling by
transmitting growth factor signals from the membrane to the actin cytoskele-
ton [190]. From the onset of Rab5 mediated receptor internalization, appro-
priate trafficking of signaling modules is essential to induce site specific Rac
activation and cytoskeletal reorganization leading to migration. In this regard,
91
EPS8 acts as a docking site for SOS1. The internalized receptor and its cargo
are then relegated to endosomal sorting, which recycles the ligand, creating
an autocrine loop that enhances mitogenic response. Alternatively, EPS8 can
also complex with RN-Tre, a Rab 5 GAP, and inhibit internalization of EGFR.
This impairs correct trafficking of EGFR and its cargo.
Proteins that interact with actin are also critical for migration. For
example, proteins such as gelsolin or EPS8 cap the barbed end of expanding
F-actin thereby regulating the pool of available actin monomers and free ends
(Chapter 1). Thus, spatial orientation and binding partners are key determi-
nants of EPS8 signaling outcome. JNK2 may directly or indirectly influence
the spatio-temporal localization of EPS8 via its endocytosis, thus affecting
actin dynamics, polarization and migration of tumor cells.
3.3.1 JNK2 Regulates EPS8 Localization
Early membrane ruffles are indicative of lamellipodia formations and
are utilized as visual cues to identify migration associated cytoskeletal reorga-
nization [190]. EPS8 is enriched at membrane ruffles when actin remodeling
is induced by serum stimulation [72]. This is due to the critical role of EPS8
in transmitting signals from Ras to Rac [175], [204], [48]. Additionally, EPS8
contributes to cytoskeletal reorganization as an actin barbed capping protein
and as an actin side chain interacting protein [50].
Previously, we reported that PyVMTjnk2+/+ cells migrate more ef-
ficiently than their jnk2 deficient counterparts. To detect if impaired traf-
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Figure 3.7: Intracellular localization of EPS8 at membrane ruffles in
PyVMTjnk2+/+ cell lines.
A). PyVMT cells suspended in serum-free media (SFM) were plated onto fibronectin
coated glass chamber slides. Cells either remained in SFM or were treated with 10% FBS
containing media for 60 mins. EPS8 primary antibody was used cytochemical analysis.
Images were captured using ImagePro 6.1 software and color overlay (EPS8=green, 60X).
B). 4T1.2GIPZ and 4T1.2shEPS8 cells suspended in SFM were plated onto fibronectin
coated glass chamber slides. Cells remained in either SFM or were treated with 10% FBS
containing media for 60 mins. EPS8 primary antibody was used for cytochemical analysis,
and the nucleus was stained with DAPI. Images were captured using ImagePro 6.1 software
and color overlay (EPS8=green, DAPI= blue, 60X) using a Nikon Diaphat CCD camera.
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ficking of EPS8 in absence of JNK2 may explain this observation, immuno-
cytochemistry was performed on serum-stimulated cells with EPS8 antibody.
Sub-confluent cells growing on fibronectin coated plates were serum starved
for six hours to down regulate basal growth factor signaling. Cells were then
serum stimulated for 60 minutes to induce Ras/PI3K signaling downstream of
RTK, leading to Rac activation and membrane ruffling [206]. At the end of the
time point, cells were fixed with 4% paraformaldehyde, gently lysed with 0.1%
triton solution and probed with anti-EPS8 antibody. Fluorescently (FITC)
tagged IgG secondary antibody was used to detect EPS8 signal.
Microscopic imaging of cell morphology, showed ruffling of the cell
membrane indicative of advancing lamellipodia in the PyVMTjnk2+/+ group
stimulated with serum (Fig.3.7). The specific localization of EPS8 signal was
visualized as green punctate signal. In agreement with our hypothesis, EPS8
localization was predominantly at peripheral membrane ruffles only in the
PyVMTjnk2+/+ cells (Fig. 3.7A). In contrast, membrane ruffling was less
prominent or entirely absent in the PyVMTjnk2-/- cells, post serum stimula-
tion, and EPS8 clustered in areas near focal adhesions (Fig. 3.7B). A similar
pattern of EPS8 localization was observed in 4T1.2 cells expressing a JNK2
shRNA. The 4T1.2 non-silencing vector (GIPZ) expressing cells with unal-
tered endogenous JNK2 showed greater membrane localization of EPS8 than
shJNK2 expressing counterparts (Fig. 3.7C and D). However, due character-
istically smaller size of the 4T1.2 cells, membrane ruffles were not as distinct
as in the larger PyVMT cells.
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Published reports and my observations suggest that in mammary tumor
cells JNK2 is essential for formation of lamellipodia, visualized as membrane
ruffling [34], [50]. At the molecular level, JNK2 ensures the appropriate traf-
ficking of EPS8 so that it can transmit signals from the membrane-bound Ras
to downstream Rac, thus catalyzing actin reorganization necessary for lamel-
lipodia formation. Rac-induced membrane ruffles demarcate the advancing
lamellopodia formed by actin remodelling.Hence with loss of JNK2, absence
of membrane ruffles is a direct indication of impaired migration potential.
3.3.2 Expression of shEPS8 Sensitizes Cells to Growth Factor Sig-
naling
We identified a role for EPS8 in JNK2-mediated migration. Localiza-
tion of EPS8 at membrane ruffles in PyVMTjnk2+/+ cells supported this
function. Unfortunately, the existing knowledge on EPS8 failed to shed any
light on this reciprocal relationship between EPS8 levels and migration in
the PyVMTjnk2-/-shEPS8 cells. Our strategy at this point was to intercept
downstream changes in RTK signaling in the PyVMTjnk2-/-shEPS8 cells.
It is well accepted that EPS8 is essential for exposing the GEF activity
of SOS1, to convert GDP-Ras to activated GTP-Ras. Activation of the Ras-
PI3K pathway leads to phosphorylation of Akt [94]. We detected a modest
increase in pAkt and pERK levels in PyVMTjnk2-/-shEPS8 cells in response
to 1% serum compared to PyVMTjnk2-/-GIPZ cells which seemed to sustain
longer in PyVMTjnk2-/-shEPS8 group (Fig. 3.8A). Both signals sustained
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Figure 3.8: Loss of EPS8 sensitizes cells to growth factor stimulation in
absence of JNK2.
A). Sub-confluent PyVMTjnk2-/-GIPZ, PyVMTjnk2-/-shEPS8 cells were serum starved
ON before stimulating with 1% FBS for 0, 0.5, 1, 2, and 4 hrs. Cells were lysed on
ice using RIPA buffer, and equal amounts of protein fractions were separated using
SDS PAGE. Membranes were probed using primary antibody as indicated. This is a
representation of 3 independent experiments. B). MTT assay showing growth profile
of PyVMTjnk2-/-GIPZ and PyVMTjnk2-/-shEPS8 in 1% FBS over 5 days. This is a
representation of 2 independent experiments.
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longer in the PyVMTjnk2-/-shEPS8 group as graphed in Fig.3.8. 1% FBS
was used since this recapitulates the serum concentration used in migration
and wound healing assays. We also performed a MTT based proliferation
assay (Fig. 3.8B). However, both cell lines had a similar growth profile. Thus
we concluded that the signaling event could partially account for the increase
in migration in these cells (Fig. 3.8B).
3.3.3 Loss of JNK2 Impairs EGF Internalization
Receptor signaling and trafficking are tightly linked to cell migration.The
migrating cell polarizes in the direction of travel, in response to extracellular
cues. Endocytosis dictates the spatial restriction of signaling events, which
is critical for cell migration [9].Upon ligand binding, receptors are rapidly
internalized via clathrin mediated pits. Internalization of activated recep-
tors allows for recycling back to the plasma membrane or for degradation.
This compartmentalizes signaling modules in spatio-temporal specific fashion
. Ligand-bound receptors demonstrate their full gamut of signaling capability
from endocytosed compartments [9].
In cells lacking JNK2 but with higher EPS8 expression, we predicted
that the overabundance of EPS8 may saturate its scaffold Abi1, the third
member of the EPS8-SOS1 complex which is essential for Ras activation and
signaling. The free EPS8 then competitively binds to RN-Tre, a Rab 5 GAP.
This inhibits Rab5 mediated EGFR internalization in an EPS8 dependent
fashion [130].
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Figure 3.9: Loss of JNK2 impairs EPS8 internalization.
A). Equal number of PyVMTjnk2+/+ and PyVMTjnk2-/- cells were plated overnight
in 8 well chamber slides in duplicates and serum starved for 6 hrs before treating them
with 100ng/ml FITC-tagged EGF at 37◦C for 15 mins (right panel) before the media was
aspirated and membrane bound ligand stripped with 0.01% acetic acid solution and imaged
under the microscope (left panel). FITC-EGF uptake was captured live using ImagePro 6.1
software and color overlay (EGF=green, 100X). This is a representative of 3 independent
experiments. B). Similar to A, except PyVMTjnk2-/GIPZ and PyVMTjnk2-/-shEPS8
cells were used and Texas Red-tagged EGF was used as a pulse. Acid stripping was done
in both cases (EGF=Red, 100X). C). Equal amount of protein from cell lysates (in RIPA
buffer) from indicated cell lines was analyzed in SDS PAGE immunoblotting. Proteins
were transferred onto nitrocellulose membranes and probed with anti-EGFR antibody to
detect endogenous receptor expression levels. GAPDH was used as the internal loading
control. This is a representative of 4 independent experiments.
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To determine the extent of EGFR internalization, receptor saturated
concentrations of FITC or Texas Red-tagged EGF ligand were used as a
pulse. Mild acid stripping was employed to remove the membrane bound
non-internalized EGF and visualize only internalized ligand. The left panel of
(Fig. 3.9A) depicts membrane bound FITC-EGF, which was not acid stripped
for ease of detection of EGF localization at the beginning of the assay. Cells
were imaged live and intracellular EGF was visualized as green punctate
staining in the PyVMTjnk2+/+ cells within 15 minutes of ligand stimula-
tion at 37◦C. This bright green punctate staining in the cytoplasm of the
PyVMTjnk2+/+ cells represents internalized EGF/EGFR complexes. In con-
trast, very few of these complexes were visible in the PyVMTjnk2-/- cells
treated in the same fashion, indicating that EGFR internalization is stalled in
absence of JNK2 (Fig. 3.9).
Another way of validating that EPS8 regulates EGF/EGFR internal-
ization in the PyVMTjnk2-/- GIPZ cell was to evaluate internalization in the
PyVMTjnk2-/-shEPS8 cells. Since both shRNA and non-silencing vectors ex-
press GFP, we used Texas Red tagged EGF in the same manner as mentioned
in the previous paragraph. In this case, the PyVMTjnk2-/- cells again failed
to show significant internalization of EGF (Fig. 3.10B). The low intensity of
signal in these cells resulted in a small amount of autofluorescence accounting
for the dull red cytoplasm. In contrast, shEPS8 expressing PyVMTjnk2-/-
cells showed robust cytoplasmic distribution of red punctuate staining indica-
tive of internalized Texas Red-tagged EGF/EGFR complex in the cytoplasm
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(Fig.3.9) suggesting lowering the levels of EPS8 facilitates internalization of
EGF.
To determine if this difference in internalization was due to any upregu-
lation of EGF receptor expression in the cell types used for the internalization
assay, we probed cell lysates for total EGFR expression using an EGFR spe-
cific antibody. As Fig. 3.9C shows, loss of JNK2 or alterations in EPS8 levels
did not affect basal EGFR expression.
3.3.4 Expression of JNK2 Abrogates EPS8-RN-Tre Interaction and
Restores Wound Repair
RN-Tre and Abi1 competitively bind to the same SH3 domain of EPS8
resulting in very different signaling outcomes [45]. This suggests that intra-
cellular levels of Abi1, EPS8, and RN-Tre must be exquisitely balanced at
the leading and the trailing edges of migrating cells to allow differential RTK
internalization and Ras/Rac signaling via the EPS8-SOS1-Abi1 tri-complex.
For this we overexpressed RN-Tre in PyVMTjnk2-/-GFPjnk2α cells that have
reinstated expression of JNK2 and reduced levels of EPS8. It may be recalled
that re-expression of JNK2 in the PyVMTjnk2-/- cells rescued their migration
phenotype. Twenty-four hours after cells were transiently transfected with the
RN-Tre vectors, a scratch wound was created. Wound closure was assessed 20
hours later and thereafter cells were collected to measure RN-Tre expression.
In the PyVMTjnk2-/-GFPjnk2α cells, migration potential was restored due to
stable expression of JNK2 (Fig. 3.10B left panel). Expectedly, overexpression
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Figure 3.10: Expression of JNK2 abrogates EPS8-RN-Tre interactions and
restores wound repair.
A). Uniform scratch wounds were made on a compact monolayer of PyVMTjnk2-/-
GFP cells, 24 hours post transient transfection with RN-Tre or RN-Tre 150 vectors. The
distance migrated by cells was calculated as the percentage of wound closure from time 0
to 20 hrs post scratch. This is a representation of 2 independent experiments. B). Uniform
scratch wounds were made on a compact monolayer of PyVMTjnk2-/-jnk2α cells, 24 hours
after they were transiently transfected with RN-Tre or RN-Tre 150 vectors. The distance
migrated by cells was calculated as the percentage of wound closure from time 0 to 20 hrs
post scratch (** p=0.0035 two-sided Student’s t-test). Western blotting showing RN-Tre
expression. This is a representation of 3 independent experiments.
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of RN-Tre partially inhibited wound closure in these cells (Fig. 3.10B center
panel). The specific effect of RN-Tre was further confirmed using the mutant
RN-Tre 150, which lacks the catalytic function of RN-Tre. As expected, in
RN-Tre 150 transfected cells wound closure was comparable to PyVMTjnk2-
/-GFPjnk2α controls confirming that our previous observation was due to
RN-Tre activity and not an artifact. With the PyVMTjnk2-/-GFP cells, sim-
ilar upregulation of RN-Tre had an additive effect on their already reduced
migration potential (Fig.3.10 A). Our data indicate that in absence of JNK2,
EPS8 preferentially interacts with RN-Tre, inhibiting internalization of RTKs,
thus impairing signal transduction. Over expression of RN-Tre further shifts
the reaction towards formation of EPS8/RN-Tre complex. This reduces EPS8-
Abi1 interactions and hinders downstream Rac signaling. The physiological
outcome is defective wound closure (Fig. 3.10A).
Our data suggest that JNK2 facilitates EPS8/Abi1/SOS1 complex for-
mation. This complex ensures signal transduction from Ras to Rac and allows
the formation of lamellipodia, which is the foot that moves the cell. Hence,
formation of membrane ruffles, an early indication of advancing lamellipodia,
occurs only in the presence of JNK2. In the absence of JNK2, EPS8 levels
are increased, promoting coupling with RN-Tre, and inhibiting EGFR inter-
nalization via Rab5 which may affect downstream signaling [69]. Once EPS8
levels are decreased by expression of shEPS8 in the PyVMT jnk2-/- cells, part
of the balance is restored, relieving the restriction on receptor internalization.
This allows more sustained signal transduction as shown by elevated pAkt and
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pERK. Lastly, ectopic expression of RN-Tre delayed wound closure, even in
the presence of JNK2, suggesting that there is a constant basal stoichiome-
try of Abi1:EPS8:RN-Tre and disruption of either EPS8 or RN-Tre interferes
with overall migration, possibly by impairing receptor trafficking. Interest-
ingly, a 3:1 intracellular ratio of Abi1: EPS8 reported elsewhere [48] supports
the notion that overexpression of EPS8 potentially saturates the available pool
Abi1. In conclusion, JNK2 by virtue of regulating the expression of EPS8 con-
tributes to intracellular trafficking of RTK-associated cargo, which we propose
is a mechanism by which JNK2 mediates migration.
3.4 JNK2 Regulates EPS8 Abundance Post-Translationally
by Altering the Stability of EPS8
Using our JNK2 knockout and knockdown models, it became apparent
that JNK2 directly or indirectly affects the level of EPS8 protein in various
breast cancer cells and even in normal mammary gland. Considering the events
that could regulate EPS8 after RTK internalization provided us with clues to
why the levels of EPS8 are higher in cells lacking JNK2. Typically in the
case of clathrin mediated endocytosis, internalized receptor and its cargo are
targeted to the early endocytotic pathway via Rab proteins, where they are
sorted for recycling or degradation. However for EPS8, a thorough literature
review failed to find any information on its fate, stability and degradation. To
support our observation that JNK2 alters EGFR/EPS8 internalization and
trafficking, and to explain how loss of JNK2 upregulates EPS8 we decided
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Figure 3.11: JNK2 regulates EPS8 abundance by altering the stability of
EPS8.
A). Subconfluent 10 cm dishes of logarithmically growing PyVMTjnk2+/+, PyVMTjnk2-/-,
PyVMTjnk2-/-, and PyVMTjnk2-/-GFPJNK2α cells were treated with 10µM cyclohex-
amide for the 3-24 hours. Cells were lysed with RIPA buffer at the time points indicated
and equal amounts of protein were resolved by SDS-PAGE and immunoblotted with
EPS8 antibody. B). Reduction in EPS8 expression was measured as a decrease relative to
untreated (0 hr) controls. This is a representative of 4 independent experiments.
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to look at EPS8 stability profile in our PyVMTjnk2+/+ and PyVMTjnk2-/-
cells. For this experiment, cells were treated with either MG-132, a proteo-
some inhibitor, or cyclohexamide, a protein translation inhibitor (Fig. 3.11A).
Since inhibition of the proteosomal degradation pathway for 24 hours failed
to show any accumulation of EPS8 protein in PyVMTjnk2+/+ cell line, sug-
gesting that proteosomal degradation is not the primary mechanism for EPS8
turnover (Fig. 3.11). However, inhibiting protein translation with cyclohex-
amide in the two different cell lines generated distinct EPS8 stability profiles.
In PyVMTjnk2+/+ cells, the EPS8 half-life was approximately eight hours
whereas, in the PyVMTjnk2-/- cells EPS8 protein remained stable up to 24 h
post treatment (Fig. 3.11) implicating that endosomal sorting targets EPS8 for
degradation in presense of JNK2. To correlate this observation specifically to
JNK2, we treated PyVMTjnk2-/-GFPjnk2 expressing cells with cyclohexam-
ide and measured EPS8 protein expression in the same fashion. As Fig. 3.11
shows, the rate EPS8 degradation increased rapidly, shortening its average
half life from above 24 hour in jnk2 lacking cells to about 12 hour, when jnk2
was re-expressed. These data strongly suggest that JNK2 targets EPS8 for
degradation, possibly via endocytotic routing to the lysosomes as a part of the
EGFR associated cargo. However, since co-immunoprecipitation assays failed
to show direct binding interactions between JNK and EPS8 (data not shown)
we do not yet know the details of how JNK2 mediates EPS8 degradation.
105
Figure 3.12: Loss of JNK2 does not alter lung metastasis in vivo.
A-D). Representative images from 5µm sections of paraformaldehyde fixed, paraffin
embedded left lung lobes of from PyVMTjnk2+/+ (left panel A, B) and PyVMTjnk2-/-
(right panel C, D) animals stained with hematoxylin and counter-stained with eosin.
Tumor cells are visible as dense compact masses with blue nuclear staining (10X). E).
Quantification of the lung metastasis (n=16) showed no significant difference (p=0.4,
two-sided Student’s t-test) F). In vitro degradation and invasion of ECM using Boyden
Chamber invasion assay was done with normal pH (7) and low pH (6) collagen matrix.
Cell invasion potential for PyVMTjnk2+/+ and PyVMTjnk2-/- cell was measured after
24 hr using 10% FBs used as chemoattractant. This is a representative of 3 independent
experiments.
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3.5 Role of JNK2 in Invasional Metastasis
3.5.1 Loss of JNK2 does not Affect Lung Metastasis in vivo
Our in vitro observations showed a strong role for JNK2 in cell migra-
tion. Next, we asked if these JNK2 regulated events were sufficient to cause
a difference in lung metastasis in vivo. PyVMTjnk2+/+ or PyVMTjnk2-/-
animals were euthanized once the target primary tumor reached a diameter
of 2 cm. Post euthanization mammary tumors and lungs were harvested.
The left lung lobes were fixed in 4% paraformaldehyde and 15 random cuts
of 5µm sections were collected every 100µm to obtain representative samples
from the entire lung lobe. The tissues were stained with haematoxylin and
eosin to detect the metastatic lesions Fig. 3.12A-D. The nuclei of the metasta-
sized mammary carcinoma cells were easily visualized as clusters of blue nuclei
amidst the organized lung tissue. As shown in Fig. 3.12E, PyVMTjnk2+/+
animals showed an increased trend for lung metastasis which did not reach
statistical significance (p= 0.409). One reason for this could be our relatively
small sample size of seven mice in PyVMTjnk2+/+ group and nine mice in
PyVMTjnk2-/- group. Moreover, there was a high degree of variability within
the groups. For example, in the PyVMTjnk2+/+ animals, the number of lung
lesions ranged between 8 to 188, while that in the PyVMTjnk2-/- animals was
2 to 95.
PyVMTjnk2+/+ and PyVMTjnk2-/- cells were tested for in vitro in-
vasine potential. In a Boyden chamber, invasive cells moved through the
polymerized collagen layer by proteolytic degradation of the matrix and at-
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tached to the bottom of the polycarbonate membrane. Neutralized collagen
matrix at pH 7-7.5 allowed moderate invasion of both PyVMTjnk2+/+ and
PyVMTjnk2-/- cells (Fig. 3.12F). Next, we modified our in vitro experimen-
tal conditions to mimic the physical environment of an endogenous tumor by
creating a more acidic extra-cellular environment. To achieve the desired con-
dition, the pH of the collagen matrix was reduced to 6. The invasive potential
of the PyVMTjnk2+/+, PyVMTjnk2-/- cells when matrix was at pH 7 versus
at pH 6 was compared. Lowering the ECM pH to 6 had dramatic effect on the
PyVMTjnk2+/+ cells, and promoted a two fold increase in invasion . Con-
versely, PyVMT jnk2-/- cell invasion was unaffected by extra-cellular acidic
pH .
To summarize our results from this section we found that JNK2 in-
creases cell migration of mammary tumor cells. The protein EPS8 which is
important for transmission of signal from the activated membrane bound re-
ceptors to the actin cytoskeleton was upregulated with the loss of JNK2 in
various tissues. However in absence of JNK2, increases in EPS8 inhibit cell
migration. Since both growth factor receptor internalization and membrane
ruffle formation were also impaired in absence of JNK2, we propose that JNK2
is essential for EPS8 mediated Ras-Rac signaling. In absence of JNK2, EPS8
interacts with an alternative complex, RN-Tre which inhibits EGFR internal-
ization. Hence overexpressing RN-Tre in PyVMTjnk2-/- jnk2a (GFP-jnk2a)
cells, we found delayed wound healing. Moreover, JNK2 also decreases ESP8
protein stability by possibly targeting EPS8 for degradation. In another set of
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related studies we found jnk2 expression increases cell invasion through acidi-
fied matrix. However, jnk2 deletion did not significantly reduce lung metastasis
in PyVMT mammary carcinoma model.
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3.6 Discussion
We identified a novel role for JNK2 in mammary cancer cell migration
involving EPS8, using the Polyoma Virus Middle T antigen model of mammary
tumorigenesis. Cell migration plays a key role in tumor invasion and metas-
tasis. The metastasis cascade starts with intravasation, where disseminated
tumor cells migrate towards the adjacent connective tissue and intravasate into
the blood vessels [241]. Current literature suggests that metastasis is an early
event in tumor progression. It initiates with an upregulation of motility genes,
priming a specific pool of tumor cells to develop a migratory phenotype. These
cells gain an adaptive advantage to respond to micro-environmental cues, nec-
essary to initiate proteolytic invasion of the surrounding matrix. Therefore,
molecules involved in cancer cell migration are potential early targets of anti-
metastasis therapy. Yet only a limited number of compounds that specifically
inhibit tumor cell migration have yielded optimistic results in clinical trials.
For breast cancer, the lung and the bone are prime organs for metas-
tasis, leading to poor prognosis and much suffering for the patient. In re-
sponse to chemoattractants, such as growth factors diffusing from blood ves-
sels or macrophages [232], disseminated cancer cells activate a complex array
of pathways. These pathways comprise of various membrane bound receptors,
downstream signaling molecules and actin binding proteins, all which act in a
spatio-temporally synchronized pattern to execute cellular motion.
JNK was first identified as a p 54 Ser/Thr kinase that phosphorylated
microtubule associated protein 2 (MTP2) when activated by cyclohexamide.
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Figure 3.13: JNK2 induces EPS8 to preferentially complex with Abi1 leading
to cytoskeletal reoranization and migration.
Abi1 and Rn-Tre compete to bind to the same SH3 domain on EPS8. In absence
of JNK2, EPS8 levels increase,saturating the available Abi1 pool. Once EPS8 binds to
RN-Tre, EGFR internalization via Rab5 is inhibited, possibly impairing Rac signaling and
migration.
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Since then, a variety of roles for the ten JNK isoform have emerged in apopto-
sis, proliferation and differentiation [42]. JNK proteins are activated by a wide
range of extracellular and intracellular stimuli such as environmental stress,
osmolarity, growth factors (EGF, PDGF, TNF) as well as by cytoskeletal pro-
teins such as tensin and frabin.
Our most important finding regarding the role of jnk in metastasis was
that the loss of JNK2 activity, particularly the JNK2 isoforms, significantly
reduced directed cell migration (Fig. 3.1). In fact, JNK mediated cell mi-
gration is observed in several developmental events such as dorsal closure of
Drosophila melanogaster and in mammalian eyelid fusion. Previously, in fish
keratinocytes, rat bladder carcinoma cells, and human MDA-MB 231 cancer
cells, JNK reportedly regulated cell migration. In the latter two instances,
JNK- mediated migration was linked to a JNK 1-induced Ser178 phosphory-
lation of paxillin [25].
We identified a specific role of JNK2 in mammary cancer cell migration
by using paired cell lines derived from tumors arising in a PyVMT transgenic
mouse model with a systemic loss of all jnk2 isoforms. Mammary tumorigenesis
is achieved by expression of the Middle T oncoprotein under MMTV promoter
in a mammary gland specific manner. An advantage of this model is its close
resemblance to the actual human disease both in tumor progression stages
and in genetic alterations. Notably Src, Shc, and PI3K genes upregulated by
PyVMT expression are often overexpressed in human breast tumors.
Under growth limiting, low serum conditions, PyVMTjnk2+/+ cells
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displayed higher migration potential than their jnk2-/- counterparts (Fig. 3.6A
and B). To specifically associate the observed phenotype to JNK2, we stably
re-expressed p54 JNK2 in the PyVMT jnk2-/- cells and convincingly rescued
the migration phenotype. These results strongly implicated a central role for
JNK2 in mammary cancer cell migration and opened up the possibility of
targeting JNK2 therapeutically (Fig. 3.3 B and C).
JNK1 and JNK2 respond to stress and growth factors very differently
and can promote apoptosis and proliferation respectively. Targeting both iso-
forms simultaneously with a pan JNK inhibitor might be detrimental for the
patient. Now, with a better understanding of the role JNK2 isoforms in metas-
tasis, we can device nano-particles that will deliver siRNA specifically against
JNK2, for a more efficient therapeutic response.
An initial microarray analysis of the tumors revealed an increase in
EPS8 in the PyVMTjnk2-/- tumors. EPS8, a 97 kDa, SH3 domain rich protein
connects growth factors receptor signaling to actin cytoskeleton via Ras and
Rac [205]. We tested jnk1 and jnk3 mRNA and protein levels in the cell lines
to clarify if EPS8 upregulation was an indirect consequence of compensatory
increase in these isoforms (Fig. 3.6C). We failed to detect any alterations in the
other JNK isoforms with the loss of jnk2 expression. Comparing EPS8 mRNA
and protein levels in the tumors and the paired set of cell lines created from the
PyVMTjnk2+/+ and PyVMTjnk2-/- tumors validated the microarray results.
Interestingly, this inverse correlation between JNK2 and EPS8 was observed in
an additional metastatic cancer model (4T1.2), and even in ductal epithelium
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of mammary gland from 5 week old wildtype and jnk2-/- Balb/c mice. How-
ever, whether this correlation is limited to the mammary tissue or is prevalent
elsewhere is yet to be determined. Database analysis showed AP-1 binding
sites on EPS8 promoter (www.cbrc.jp/research/db/TFSEARCH.html) It may
be recalled that AP-1 is a transcription factor downstream of JNK1 and 2. It
is well accepted that JNK2 binds to and degrades c-Jun, a part of the AP-1
complex. Thus, absence of JNK2 stabilizes c-Jun and increases AP-1 activity
leading to EPS8 transcription.
Notably, this is not the first time JNK is associated with the migration
machinery. Other known cytoplasmic targets of JNK that regulate migration
include paxillin [91], actin binding protein spir, and microtubule associated
proteins DCX , MAP1B and MAP2. Unfortunately, we could not validate the
observations of Huang et al. showing JNK dependent Ser 178 phosphorylation
is key an event in cell migration (data not shown). No difference in FAK and
Src expression or activation was recorded in our studies. This could be due
to that fact that the previous authors were using pan-JNK inhibitors and not
systemic knockdowns. Alternatively JNK1, not JNK2 maybe the key isoform
regulating FAK-paxillin pathway, hence remained unaltered in our jnk2-/-
model.
EPS8 enhances Ras-Rac signaling in response to growth factors. One
would presume that with the loss of JNK2 and concomitant increases in EPS8,
actin-based cell migration would be higher. However, this was not the case in
our model. Emerging evidence supports a multifunctional role for EPS8 rang-
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ing from EGFR signaling and trafficking, to Rac signaling and actin capping.
These findings encouraged us to investigate the role of EPS8 in JNK2-mediated
cell migration. Several attempts to co-immunoprecipitate EPS8 with JNK2
and vice versa did not show any binding, suggesting an indirect interaction
(data not shown). However, this does not necessarily exclude the possibility
that the complex formation is regulated dynamically in vivo and is hard test
to under experimental conditions. This is not unusual since most other stud-
ies also failed to successfully co-immunoprecipitate endogenous EPS8 and its
binding partners [95]. Therefore, we asked: 1) if the level of EPS8 expression
is the key determinant of cell migration in the absence of JNK2, and 2) how
loss of JNK2 leads to an increase in EPS8 expression.
To answer the first question we knocked down EPS8 expression in the
PyVMTjnk2-/- cells almost to the levels expressed in PyVMTjnk2+/+ cells.
Expression of shEPS8 in cells lacking JNK2 increased cell migration. There
are various possibilities of how JNK2 could influence EPS8’s cellular func-
tion because EPS8 can be a signaling, docking, trafficking and actin capping
protein.
Identifying a few of the many endogenous activities of EPS8 suggests
the presence of a three pronged pathway depending on its binding partners.
First, EPS8 directly interacts with F-actin and caps actin in an Abi1 dependent
manner. Second, it plays a critical role in RTK signaling in Abi1-SOS1-PI3K
dependent manner. Lastly, it is closely involved in RTK trafficking when
complexed with the RN-Tre, instead of Abi1. JNK2 could influence any or all
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of these interactions to regulate cell migration.
During my progression through this research, the importance of cel-
lular localization of proteins became more apparent. The cell has discrete
compartments with specific protein demography, and signal transduction is a
means to rapidly transmit the information between them. Integrity of these
compartments are maintained by protein sorting based on peptide motifs or
post-translational modifications.
Localized activity of protein is important for correct cytoskeletal reor-
ganization. During cell migration, rapid bursts in synthesis of actin filaments
are necessary for lamellipodia extension. Several in vitro and in vivo studies
have shown that the effector domain of the amino terminus of EPS8 (648-
821) has a high affinity (in nanomolar range) for actin filament barbed end.
EPS8 also caps fast growing barbed ends of F-actin in presence of Abi1. Un-
regulated amount of F-actin capping will limit the growth of the filament,
impairing lamellipodia extension. Therefore, localization of EPS8 is critical
for cell migration. Incorrect localization of EPS8 may lead to global or random
restriction of actin filaments, disrupting expansion of lamellipodia and forma-
tion of membrane ruffles. Notably, the lack of membrane ruffles and reduced
migration of PyVMTjnk2-/- cells might be an outcome of such mislocalized
EPS8. Our EPS8 localization data, as shown in Fig. 3.7, strongly support this
argument.
Contrary to the current understanding of EPS8, higher expression of
ESP8 did not correspond to increased migration in the PyVMTjnk2-/- cells,
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nor did ESP8 localize to emerging lamellipodia. We speculated that in the
absence of JNK2, EPS8 does not participate in the Abi1-SOS1 complex, that
mediates Ras-Rac signaling. JNK2 can directly influence EPS8’s binding pref-
erence. Alternatively, by regulating EPS8 levels JNK2 modulates EPS8 com-
plex formations. Furthermore, little information exists on EPS8 stoichiometry
under physiological conditions except that EPS8 and Abi1 are present in a 1:3
ratio inside the cell [48]. This suggests the existence of an exquisite balance
between endogenous EPS8 and Abi1 which facilitates the Ras-Rac signaling
and migration. When EPS8 disrupts that balance and saturates Abi1, other
EPS8 complexes arise. These complexes may not communicate with the actin
cytoskeleton, thus impairing migration. In our model, with loss of JNK2,
only EPS8 but not Abi1 levels (data not shown) increased. Therefore, there
might be a possibility of disruption of the aforementioned balance affects cell
migration in the PyVMTjnk2-/- cells.
EPS8 being proximal to the plasma membrane integrates EGFR signal-
ing via Rac by entering into a complex with Abi1-SOS1. EPS8 also engages in
Rab 5 mediated EGFR trafficking by forming a complex with RN-Tre, a Rab
5 GAP. However, the EPS8-RN-Tre binding is an inhibitory interaction where
ligand bound EGFR internalization is inhibited due to reduced Rab5 activity.
The net outcome of EPS8 binding to RN-Tre, instead of Abi1, is inhibition of
EGFR internalization. This phenomena was detected in our model. Monitor-
ing fluorescently labeled EGF uptake via its receptor, we demonstrated, that
PyVMTjnk2+/+ cells internalized more EGF than their jnk2-/- counterparts.
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This suggests that in absence of JNK2, EGFR is not internalized. Binding of
EPS8 to RN-Tre will cause a similar effect. To confirm this correlation we
overexpressed RN-Tre in the JNK2 expressing cells. Overexpressing RN-Tre
in the PyVMTjnk2-/-GFPjnk2α cells decelerated wound closure (Fig. 3.10).
It may be recalled the re-expression of the p54 JNK2 isoform had rescued
the migration phenotype in these cells, which are now inhibited by RN-Tre
expression.
Specificity, strength and duration of EGFR and other RTK signaling
are dependent upon internalization, endocytosis, ubiquitination and subse-
quent degradation of the receptor. Internalized EGFR is known to generate
almost the entire gamut of EGFR signal outputs, resulting in localized activa-
tion of Shc, Grb2, SOS1, and MAPK cascade. Notably, EGF-activated EGFR
remains at the plasma membrane only briefly (5 to 10 min) but remains as-
sociated with the endosome for over an hour. Similar to plasma membrane
associated activation of EGFR, activation of endosome-associated EGFR sup-
ports cell survival by stimulating the PI3K-Akt and ERK pathway. In fact,
expression of dominant negative dynamin, which inhibits EGFR internaliza-
tion reduces ERK activation in HeLa cells. Subsequently, one would expect
increased MAPK and Akt activation when RTK signals are routed through the
EPS8-SOS1-Abi1 complex rather than in the EPS8-RN-Tre-Rab5 complex. In
our case, 1%serum induced activation of both pAkt and pERK were quantifi-
ably higher in PyVMTjnk2-/-shEPS8 cells as compared to PyVMTjnk2-/-
GIPZ cells 3.8. This signaling outcome correlates well with our earlier EGF
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internalization data in these cells. However, this did not alter their prolifer-
ation. The case for Akt is complicated by the contradictory functions of its
three isoforms Akt1, Akt2 and Akt3 [98]. Recent findings implicate Akt2 in
inducing mammary cancer cell migration [98]. In ErbB2 transgenic mouse
mammary tumors Akt1 is a metastasis suppressor [251] while Akt2 enhances
metastases [140]. Akt3 activation is more pronounced in estrogen receptor
negative breast cancer cells and accounts for the more aggressive phenotype
of these tumors [167].
The true significance of the signaling data is difficult to evaluate. The
precise kinetics of MAPK or Akt signaling necessary for cell migration is not
well explored. Some studies speculate that membrane vs. endosomal signaling
leads to a growth vs. migration effect, but this requires further analysis.
Finally, if the presence of JNK2 is essential for RTK endocytosis, then
the signaling complex associated with the RTK is also targeted to the endocytic
vesicles. This would explain a lower EPS8 protein level in the PyVMTjnk2+/+
cells. So far, there is no report in the literature regarding EPS8 stability
or degradation. Thus, we suggest that JNK2 targets EPS8 to the endocytic
pathway thereby decreasing the stability of the protein. In similar lines, mono-
ubiquitination of another EPS8 family member EPS15 by NEDD4, an E3 ligase
similar to Itch, was necessary for trafficking of EPS15 into the endosomal-
lysosmal pathway. By activating E3 ubiquitin ligase Itch, JNK2 could further
influence EPS8 trafficking.
To test the role of JNK2 in EPS8 degradation, we used MG132 treat-
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ment, to stall proteosomal degradation. We did not detect any accumulation
of EPS8 in either PyVMTjnk2+/+ or PyVMTjnk2-/- cell lines. However, in-
hibiting protein translation with cyclohexamide resulted in a different EPS8
degradation profiles. Indeed, EPS8 half life was significantly reduced in JNK2
expressing cells (Fig. 3.11). To our knowledge, this is the first report on EPS8
protein stability and the effect of JNK2 on protein translation. Further re-
search is necessary to elucidate the exact mechanism by which JNK2 targets
EPS8 translation.
So far the biological outcome of the loss of JNK2 is determined by
a balance between EPS8-Abi1-SOS1 (promoting migration) or EPS8-RN-Tre
(inhibiting receptor internalization). Critically, how JNKs regulate their sub-
strates to induce migration has been outstanding. Here we show that JNK2 ac-
tivation accelerates growth factor induced cell migration by modulating EPS8
levels. This is probably depends on JNK-mediated routing of EPS8 into spe-
cific complexes which regulate Ras-Rac signaling.
Cell migration is one of the many steps in the metastasis cascade (1.2).
Based on the role of JNK2 in promoting migration we decided to evaluate
its effects on both cell invasion and metastasis. Preliminary studies did not
show any significant difference in cell invasion through collagen due to loss
of JNK2. However, slight modification of of pH of the ECM gave us some
interesting insights. Extracellular pH of tumors is typically more acidic than
normal tissues. This acidic pH could enhance the invasive and migratory
behavior of cells in in vitro and in vivo. In fact, in highly metastatic breast
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cancer cells, acidic pH was correlated to larger lysosomal vesicles and increased
metastasis. Our data suggests that pH of the extracellular matrix may have a
trophic effect on metastasis. Therefore we found cell invasion through type-1
collagen increases with lower pH. This can be related to enhanced secretion
of MMPs. Surprisingly, the loss of JNK2 had greater inhibitory effects on cell
invasion at pH 6 than at pH7.5. Statistical analysis of our data revealed that
murine mammary cancer cells are sensitive to pH-induced invasion in a JNK
dependent manner.
Lastly, to assess the role of JNK2 in promoting metastasis in vivo, we
quantified the incidences of lung metastasis in the animals. Our results failed
to detect an increase in metastatic lesions in the lungs of the PyVMTjnk2+/+
mice, compared to their jnk2-/- counterparts. Overall we observed less metas-
tasis than what others have reported in the literature which may be due to
the strain of mice we used or abnormal expression of MT antigen itself in the
metastasized cells.
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Chapter 4
Role of JNK1 in vivo metastasis
During metastasis, cells from the primary tumor must successfully com-
plete a series of sequential steps to reach its target organ. These steps include
shedding of cells from the primary tumor into the circulation (the seed), sur-
vival of those circulating tumor cells, their arrest in a highly vascularized new
organ (the soil), extravasation into the surrounding tissue, colonization and
growth in the new site, and finally vascularization of the metastatic secondary
tumor [13].
The overall goal of my research is to study the role of JNK isoforms
in mediating mammary cancer metastasis. In the previous chapter, (Chapter
3), it was reported that with the loss of JNK2, tumor cell migration decreased
in vitro. However, such loss of JNK2 did not significantly alter the number
of metastasis in the lungs of the PyVMT mice. Since we are interested in
understanding the overall role of JNK in metastasis, the next step was to
study JNK1. However, we opted for a different experimental animal model
where one could study both early and later steps of metastasis.
The 4T1.2 model involves injecting cancer cells into experimental ani-
mals either orthotopically (e.g at the mammary fat pad) or directly into the
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circulation. Orthotopic injection reflects a ‘spontaneous metastasis model’,
while intravenous injection models the later stages in metastasis and is re-
garded as ‘experimental metastasis model.’ The endpoint of both these models
is formation of visible metastases at the secondary site, in this case the lung
[135].
The limited evidence for a role for JNK1 isoforms in promoting metasta-
sis is contradictory and very tissue specific. However, based on the knowledge
that JNK1 is a key regulator of apoptosis [42], that its upstream kinase MKK4
is a tumor suppressor [29], and loss of JNK1 increased tumorigenesis in some
skin cancer models [31], [44], [17], [247], I propose the following hypothesis:
Hypothesis: Deficiency of JNK1 increases tumor growth and metastasis
of murine mammary carcinoma in vivo.
To test my hypothesis, I propose the following specific aims
Specific Aim 1: Determine the effect of JNK1 on mammary carcinoma
proliferation and invasion in vitro.
Specific Aim 2: Determine the role of JNK1 in promoting tumor growth
and metastasis in vivo.
Specific Aim 3: Determine the mechanism(s) by which JNK1 regulates
tumor growth and metastasis.
The 4T1.2 tumor cell line is characterized by their high propensity to
form lung and bone metastasis for orthotopic and intravenous injections into
experimental animals [135]. The 4T1.2 is a sub clone of the original 4T1 cells
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which was developed from a spontaneous mammary tumor in a Balb/cfC3H
mouse [135]. This particular model is clinically relevant since it reflects the
metastatic spread from the mammary gland to distant sites and closely re-
sembles the human disease. Moreover, because the 4T1.2 cell line is syngeneic
with the Balb/c mouse, this model allows investigaton of in vivo metastasis
in an immunocompetent model. Another useful feature of this model is that
the metastasis to the bone is associated with hypercalcaemia and secretion
of parathyroid hormone-related protein, two classic characteristics of human
breast cancer metastasis to bone [135].
4.1 Effect of Loss of JNK1 on 4T1.2 Cell Proliferation
and Invasion in vitro
Rationale and Significance: Tumor cells degrade their surrounding ex-
tracellular matrix and basement membrane to escape the primary tumor. Ma-
trix invasion is initiated by alterations in integrin signaling in the tumor cells
[20], [107], [3]. This upregulates the expression of matrix degrading proteases
such as MMP2, MMP9, or MMP13 etc via transcription factors like AP-1 [31]
. The invasive phenotype is associated with an altered gene expression profile.
JNK, being an upstream activator of transcription factors like AP-1, becomes
a key suspect. JNK signaling can regulate cell invasion by regulating tran-
scription of MMPs and other proteases. However, net the outcome of JNK
activation remains unclear since it can both promote or suppresses metastasis
[3], [39]. For example, in trophoblastic cells TNF-induced MMP-9 expression
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Figure 4.1: JNK2 expression remains unchanged with JNK1 knockdown.
A). 4T1.2 is a sub population of cells from a spontaneous Balb/c mammary tumor
which were selected for their aggressive bone metastasis potential. Cells retrovirally
transduced with jnk1 specific shRNA (4T1.2shJNK1) and a non-silencing vector (SCR).
Puromycin-resistant stable clones were assayed for maximal knock-down of gene expression
at both protein (A and B) and mRNA levels (D). C). Shows that shJNK1 did not alter the
expression of JNK2 in these cells. JNK2 specific antibody was used to detect both p46 and
p55 bands. GAPDH was used as loading control.
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and activity was inhibited by JNK signaling [32]. Specifically, JNK1 stimu-
lated cell invasion by inducing FoxM1 mediated transcription of MMP2 and
MMP9 in osteosarcoma cells [230].
4.1.1 JNK1 Negatively Regulates Invasive Potential of 4T1.2 Cells
without Altering Cell Proliferation in vitro
JNK signaling is critical for cell proliferation, cell cycle progression
and proteolytic invasion [42]. First, retrovirally transduced 4T1.2 cells with
shJNK1 selected stable clone with about 70% reduction in JNK1 expression
both at protein and mRNA levels (Fig 4.1 A and C). Next, we evaluated
whether the reduction in JNK1 expression altered the levels of JNK2 expres-
sion in these cells. As shown in Fig. 4.1 C, loss of JNK1 did not alter the
levels of JNK2 protein levels in the 4T1.2 cells.
To determine the role of JNK1 in 4T1.2 cell invasion through ECM, we
used a transwell chamber invasion assay with MatrigelTM as the extracellular
matrix and complete serum as the chemoattractant. The Boyden chamber
assay recapitulates an in vivo scenario by providing a chemical gradient to-
wards which cells invade. The MatrigelTM , comprised of collagen IV and
laminin, activates integrin signaling and eventually leads to MMP activation
and proteolytic degradation of the matrix. As illustrated in Fig. 4.2A, reduced
expression of JNK1 significantly increased the invasive potential of 4T1.2 mam-
mary carcinoma cells compared to the non-silencing vector controls (Scr) (p ≤
0.002) in sevral highly reproducible experiments. In multiple experiments we
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observed similar increase in the invasion potential of the shJNK1 expressing
cells. Proteolytic invasion of the ECM is a key step in metastatic cascade
indicating that our in vitro findings predict a significant role for JNK1 in sup-
pressing metastasis in vivo. Local invasion is perpetuated my matrix degrading
enzymes like the MMPS. Gelatin zymography is a sensitive method to detect
MMP activity where the proteolytic degradation of substrate gelatin can be de-
tected in a non-SDS gel. However both gelatin zymography and immunoblot-
ting failed to detect any significant difference in expression and activity of two
of the most common matrix degrading enzymes namely, MMP2 and MMP9
(data not shown). Additionally, difference in expression of other published
JNK targets including PTEN, Akt2, urokinase plasminogen activator (UPA)
and EPS8 were less than two-fold based on immunoblotting and microarray
results (data not shown). Furthermore, migration potential of these two lines
was comparable in fibronectin matrix based transwell migration assays (data
not shown). Interestingly, there was detectable increase in A Disintegrin And
Metallopeptidase 10 (ADAM10) expression in the shJNK1 expressing cells as
detected by western blotting (unpublished data) and immunohistochemistry.
Notably, ADAMs are multidomain metalloproteases that cleave membrane
bound proteins at the cell surface. In addition, they degrade extracellular ma-
trix, both of which are critical for tumor cell invasion and metastasis. JNK1
phosphorylates c-Jun, which in turn activates downstream AP-1 transcription
factors, thus increasing proliferation [42]. JNK2, on the other hand, binds
to c-Jun in unstimulated cells and degrades it, thereby stalling proliferation
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[198]. Since, in vitro cell invasion assays span 15-24 hours, an increase in cell
proliferation or apoptosis could contribute to the aforementioned outcome. To
test cell viability, an assay based on reduction of a tetrazole salt (MTT) to an
insoluble formazan by the enzyme reductase found in active cells, was utilized.
Reduced expression of JNK1 did not affect cell proliferation, as determined by
their comparable growth over 72 hours (Fig. 4.2B). These data showed that
the intrinsic proliferation of the two cell lines was comparable even with lower
JNK1 expression. Taken together, our in vitro data show that reduced expres-
sion of JNK1 enhances cell invasion through MatrigelTM but does not alter
cell proliferation or expression of other JNK isoforms.
4.2 JNK1 Promotes Tumor Growth and Metastasis in
vivo
Rationale and Significance: Breast cancers cells preferentially metasta-
size to specific organs such as the lung, bone and brain during metastasis [161],
[245], [170], [139]. Both the cancer cell and the micro-environment contribute
to the colonization of the of tumor cells at the new site [107]. Our earlier in
vitro results established that reduction of JNK1 promotes cell invasion. How-
ever, cell invasion is just one step in the elaborate metastasis cascade. We
then asked if the in vitro invasive phenotype would be observed in vivo, where
the stromal microenvironment, a dynamic source for growth factors, cytokines,
and chemokines, presents a different scenario to which the tumor cells must
adapt. Often the in vitro results are hard to replicate in vivo due to tumor-
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Figure 4.2: 4T1.2 cell invasion increases with shJNK1 expression.
A). Equal number of 4T1.2Scr cells and 4T1.2shJNK1 were placed on MatrigelTM
coated inserts, and were allowed to invade the matrix towards a chemoattractant (10%
FBS) for 24 hrs. Invaded cells were fixed, stained, and counted (**p ≤ 0.002, two-sided
Student’s t-test). This is a representation of 2 independent experiments B). Equal number
of 4T1.2Scr and 4T1.2shJNK1 cells were plated in growth medium (10% FBS) and
viability was measured using a MTT-based assay over 72 hrs. No significant difference in
proliferation rate was observed. This is a representative of 3 independent experiments.
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Figure 4.3: JNK1 deficiency accelerates primary tumor growth.
0.1 million 4T1.2Scr or 4T1.2shJNK1 cells were orthotopically injected into the 4th
mammary fat pad of 6-8 week old Balb/c mice. Animals were harvested when tumors
reached target volume of 1cubic cm. A). Kaplan Meier plot showing survival over time
is significantly greater in the 4T1.2 Scr tumor group compared to shJNK1 group (p ≤
0.0001, n=28) B). Average tumor volume from the time of first palpation till the tumor
reached target volume. C). Spontaneous lung metastasis assessed by intra tracheal India
ink injection and manual counting of surface lesion, did not show significant difference.
(p=0.239, n=16)
130
stroma interactions and systemic effects of immune surveillance. In a classic
example, in vitro studies demonstrated a cooperative role for JNK1 in Ras-
mediated transformation [137]. However in vivo studies by the same authors
found JNK1 to play a completely opposite role [42]. In addition to growth fac-
tor and cytokines generated by the microenvironment, hypoxia and low pH,
contributed by the solid tumor itself can activate JNK [148], [134]. Hence,
to elucidate the role of JNK1 in mammary tumorigenesis and metastasis we
utilized an in vivo mouse model.
To do this we employed orthotopic delivery of tumor cells into the
mammary fatpad, creating a primary tumor that spontaneously metastasizes
to the lung and the bone.
4.2.1 JNK1 Deficiency Increases Orthotopic Tumor Growth
Commonly immune-deficient mice are used for orthotopic inoculation
of human or murine cells to trace the path of breast cancer spread. Since
cancer is a systemic disease, bypassing the immune-surveillance system is not
clinically relevant. The 4T1.2 cells originated as a spontaneous mammary tu-
mor in Balb/c mice. Therefore, these cells can be orthotopically injected into
syngenic mice providing a realistic scenario to study spontaneous metastasis.
In a blinded study, 4T1.2 shJNK1 and non-silencing vector expressing cells
(Scr) were injected into the 4th mammary fat pad of 6-8 week old Balb/c
mice. Tumors were palpable in both groups by 10-15 days post injection. Pri-
mary tumor sizes were measured three times each week using calipers, until
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they reached a minimum volume of 1 cubic cm. Excised tumors were weighed
after sacrificing the mice. In most cases, the target size corresponded to about
1000 mg (1gm) tumor mass. Twenty-eight out of the 30 animals that were
orthotopically injected with cells developed a tumor at the site of injection.
Small hairpin-mediated reduction in JNK1 expression in the injected tumor
cells greatly amplified tumor growth (p ≤ 0.0001) (Fig.4.3A). The difference
in the tumor volume over time in vivo, suggested that the 4T1.2shJNK1 tu-
mors responded to the local proliferation, angiogenesis and survival signals
from the microenvironment more effectively than their 4T1.2Scr counterparts.
Mice injected with shJNK1expressing cells showed a dramatic increase in tu-
mor growth rate, compared to their controls (Fig.4.3B). The tumor latency
of shJNK1 group was almost half of that of Scr control group since all of the
JNK1 deficient group reached target tumor size by day 40 compared to day
70, in the control group (Fig.4.3A). Next, the tumor burden in the lungs due
to spontaneous metastasis was quantitated by manually counting the visible
nodules after infusing the lungs with India ink. Metastatic lung nodules were
grossly visible in majority of these animals, since the 4T1.2 cell line is known
to aggressively metastasizes to the bone and lung [135]. Bone lesions were also
detectable upon histological staining (data not shown). Metastases to other
organs such as the stomach and occasionally liver were observed visually. In
the majority of the animals an enlarged spleen up to five times the size of nor-
mal spleen of age-matched Balb/c mice, was observed. However, differences
in the number of spontaneous lung metastasis resulting from the orthotopic
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tumors in the two groups did not reach significance (p=0.239) (Fig.4.3C).
Nonetheless, a distinct trend was observed favoring a higher incidence of lung
lesions in the shJNK1 group.
4.2.2 JNK1 Signaling Alters Homing of Tumor Cells to the Lung
Overall metastasis is an inefficient process due to the rate limiting steps
of cancer cell growth at the secondary site [107]. Earlier, we failed to detect
any increase in spontaneous lung metastasis in the shJNK1 group in vivo.
One possible explanation for the disparity between in vitro and in vivo find-
ings could be that JNK1 only affects the later stages of tumorigenesis, such as
homing and growth of the tumor cells in the secondary site. These later steps
are hard to clarify in the orthotopic model. The ‘experimental metastasis’
model, on the other hand, excludes the initial steps of dissemination or in-
travasation and directly allows one to study the lodging of tumor cell in a new
organ, extravasation into the surrounding tissue, and growth into secondary
metastases at the new site.
To test this, tTumor cell lines expressing shJNK1 or non silencing vec-
tor were injected into 6-8 week old Balb/c mice via the lateral tail vein. Again,
India ink lung perfusion was used to visualize metastatic nodules in the lung af-
ter animals were sacrificed 15-17 days post injection. Mice injected with either
non-silencing vector or shJNK1 expressing cells experienced lung metastases,
as visualized in India ink stained lungs illustrated in Fig 4.4A. In contrast
to the orthotopic injections, the number of lesions were remarkably higher in
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Figure 4.4: Quantification of lung metastasis by tracheal India ink injection
post intravenous injection of clonal cells.
0.1 million clonal cells were injected into the lateral tail vein of 6-8 wk old mice
and allowed to circulate in the bloodstream. Mice were euthanized on day 15 post injection
and lungs were analyzed for the presence of metastatic tumors. India ink was injected
intra-tracheally into the lung, staining lung tissue but not mammary epithelial tumor
cells. A). Metastases were visualized as white spots on black ink-stained tissue. Lesions
were manually counted. B). Lung metastases post intravenous (lateral tail vein) injections
show significantly (**p ≤ 0.0043 two-sided Student’s t-test) higher lung metastasis in the
shJNK1 group (n= 30).
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the 4T1.2shJNK1 injection group (p= 0.0031) (Fig 4.4 B). A finer, size-based
analysis of metastases reaffirmed that the shJNK1 group had indeed a) greater
number of macroscopic surface lung lesions, b) each foci had a larger radius
(data not shown). Thus, our in vivo data show that JNK1 deficiency greatly
increases primary tumor growth and lung metastasis in the 4T1.2 model.
4.3 JNK1 Mediates Tumor Growth and Metastasis by
Transcriptional Regulation of Chemokine Receptor
5 (CCR5)
Rationale and Significance: Breast cancer metastasis to the lung or the
bone is a multigenic program. Differences in our in vitro proliferation and in
vivo tumor growth data suggest that 4T1.2 shJNK1 cells differentially respond
to or manipulate the host microenvironment to gain a proliferative edge. It
is well accepted that in solid tumors, angiogenesis, described in introduction,
significantly contributes to increased tumor growth, invasiveness and metasta-
sis [120], [107], [101]. Fast growing malignant tumors stimulate the formation
of new capillaries to provide itself with oxygen and nutrients. The net out-
come of increased angiogenesis is enhancement of proliferation, migration and
proteolysis of endothelial cells, which then form new capillaries to nourish the
tumor [108].
Various members of the MAPK family are implicated in promoting
angiogenesis [223]. The role of JNK is controversial, with incidences of both
positive and negative regulation of angiogenesis. Uchida et al., showed that
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JNK inhibition with SP600125 leads to down-regulation of MMP2 activity,
reducing endothelial cell proliferation and migration [223]. An actively growing
breast tumor often resembles a ‘wound that fails to heal’ [15]. The stroma,
specifically, the connective tissue surrounding the tumor, continually secretes
autocrine and paracrine factors that recruit varous kinds of cells including
mesenchymal cells to aid tumorigenesis [22]. In these lines, recent evidence
showed that when tumor cells are co-cultured with mesenchymal stem cells
(MSC), their invasive and metastatic capacity increases [119]. The reason for
such increase may be local paracrine factors like chemokine ligand 5 (CCL5)
secreted by MSC or the breast tumor itself, that promote breast cancer cells to
metastasize to and colonize in the lung. The clinical relevance of this finding is
that the elevated CCL5 levels detected in the plasma of breast cancer patients
correlated with their poor prognosis. Moreover, local concentrations of CCL5
was detectably higher in the tumors of the invasive disease compared to the
DCIS [141].
4.3.1 Neovascularization is Unaffected by JNK1 Repression
Endoglin (CD105), a 180 kDa homodimeric membrane glycoprotein, is
a powerful and highly specific marker for activated endothelium hence and is
used to measure neovascularization [158],[155], [153]. It functions by binding
to TGF beta signaling pathway and is overexpressed in highly proliferating
endothelial cells in culture, as well as in endothelial cells from the angiogenic
blood vessels within tumor tissues [153]. Since CD105 was also reported in
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Figure 4.5: Comparable expression of CD105 in 4T1.2 orthotopic tumors.
A). A 5 micron section of paraffin-embedded tumor tissue was stained by indirect
avidin-biotin immunoperoxidase using CD105 specific primary antibody and hematoxylin
counter staining. Intense positive immune reaction (brown) was evidenced in the fine
tumor vasculature in both sets of tumors (original magnification= 20X). B). Quantification
of CD105 positive vessels was performed by counting all the vessels in each field (p=
0.34 two-sided Student’s t-test). Three tumors in each group were analyzed for CD105
expression.
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breast tumor samples , it served as a good marker for neovascularization in our
model [197]. To determine the status of angiogenesis in the orthotopic tumors,
we used anti-endoglin antibody to stain primary tumor sections. Paraffin em-
bedded tumor tissues were sectioned and analysed using a specific endoglin
antibody, in a blinded experiment. Endothelial cells in the tumor tissue were
detected by positive CD105 immunoreactivity (brown stain). Blue haema-
toxylin stain was used to demarcate the nucleus of tumor cells. In Fig.4.5A,
a cross sectional representation of the primary tumor tissues from each group
is shown. The specificity of the antibody is evident from the highly localized
staining of the vessels in the tissue section. Newly formed vessels that stained
positively for CD105 were prevalent in both sets of tumors. Dense vessel for-
mation was observed towards the periphery of the tumor cross-sections rather
than the center. Immunohistological staining was performed using multiple
sections from five different tumors from each orthotopic injection group. A
preliminary quantification of the total number of vessels in each tumor cross-
section, irrespective of their size demonstrated a slight increase in vasculature
in the 4T1.2 Scr tumors compared to the 4T1.2shJNK1 group which did not
reach statistically significance (Fig. 4.5 C ). However since angiogenesis could
be due to sprouting from preexisting vessels or enlargement of the older vessel,
the immunohistochemistry results will be analyzed for intensity of stain and
vessel size of to obtain further information on the role of JNK1 in angiogenesis.
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Figure 4.6: Microarray Analysis of JNK1 mediated gene deregulation identifies
CCR5 as a potential target.
Paired sets of tumors, generated by orthotopic injection of the clonal cells, were
used for microarray. Amongst other genes, CCR5 was upregulated 2 fold in the shJNK1
tumors. A) 4+4 Scrambled and shJNK1 tumors were lysed with RIPA lysis buffer and
immunoblotted for CCR5.GAPDH was used as loading control. B). Scrambled and shJNK1
tumors were lysed with RIPA lysis buffer and immunoblotted for pAkt. GAPDH was used
as a loading control. C).1 million 4T1.2 Scr and 4T1.2 shJNK1 cells were plated and serum
starved overnight, followed by stimulation with 10% FBS for 60 mins. Cells were harvested
in RIPA lysis buffer and analyzed by immunoblotting with specific anti pAkt (Ser273)
antibody using GAPDH as a loading control. The right panel shows quantification of pAkt
band intensity normalized to GAPDH bands in cell lines.
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4.3.2 Identification of CCR5 as a Novel Target for JNK1
Since JNK1 activates transcription factors [42], we expanded our study
by screening for the broad spectrum of genetic alterations brought forth by
decreased JNK1 expression. We performed a microarray analysis with two sets
of cDNA derived from each group of orthotopic tumor. Microarray analysis
showed some very interesting candidate genes known to regulate development
and cancer.
One candidate gene amongst them, the Chemokine receptor 5 (CCR5)
was of interest based on its established role in metastasis and correlated higher
expression difference we observed in the shJNK1 tumors (2 fold). This result
was validated using immunoblotting. As illustrated in Fig 4.6A, expression of
CCR5 protein was higher in three specimen samples from the shJNK1 tumor
group compared to their counterparts. Based on an earlier observation by
Karnoub et al., [119], where increased activity of tumor CCR5 and stromal
CCL5 lead to an increase in tumorigenesis and metastasis, we proposed that
upregulation of CCR5 in the the shJNK1 tumors could induce a similar effect
in vivo. Studies have shown that upregulation of CCL5 induces an increase
pAkt, a survival and proliferation signal in the mammary tumor models [119].
To test this hypothesis, we utilized tumor protein lysates and measured
levels of activated Akt using specific phospho-Akt antibody. We consistently
observed higher pAkt levels in the five 4T1.2shJNK1 tumors compared to
the non-silencing vector controls (Fig 4.6B). We also observed a striking in-
crease in pAkt levels within 60 minutes of addition of serum (10% FBS) in the
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4T1.2shJNK1 cells line compared to the vector control (4.6C). Additional time
course experiments are necessary to interpret the significance of this observa-
tion. However, the preliminary observation supports a CCR5-CCL5, tumor-
stroma communication which may mediate both increased tumor growth and
metastasis in 4T1.2 shJNK1 expressing tumors.
Overall, the results discussed here suggest that in contrast to JNK2,
expression of JNK1 suppresses metastasis both in vitro and in vivo. We found
that loss JNK1 increased cell invasion, tumor growth and lung metastasis in
the 4T1.2 mammary tumor model. In addition, we identified CCR5 as a novel
target for JNK1 which could play a major role in harnessing stromal signals
that renders a more aggressive phenotype to the JNK1 deficient cells.
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4.4 Discussion
Metastasis is the main cause of death from cancer. This stage of tumor
progression is incredibly complex and least treatable. Not surprisingly, the few
tumor cells that overcome multiple physiological barriers in their path and mi-
grate from the primary tumor site into the circulation and successfully invade
distant organs are very resistant to chemotherapeutic drugs. The complex
process of metastasis is often studied in vitro in terms of cell migration and
cell invasion. However, to fully understand the efficacy of a potential thera-
peutic target, the enormous contributions of the tumor microenvironment and
the host immune system in perpetuating malignancy must be considered. The
MAPK family along with PI3K and Akt are key signaling systems involved
in regulating various steps in the metastatic cascade [44]. A better under-
standing of their mechanisms of action in cancer and metastasis will facilitate
development of novel therapeutic strategies.
The MAPK family members, ERK, JNK and p38 kinase are well known
effectors of growth factor and stress mediated signaling in normal and cancer
cells [251], [203], [165], [222]. Although elevated ERK activity in human can-
cers is well known, it is the new-found role of JNK in tumorigenesis, especially
oncogene-mediated cell transformation that is causing excitement in the field
[86], [77], [16], [251], [247], [17], [39]. The three jnk genes have 10 isoforms with
tissue and stimulus-specific functions. A direct role of JNK has been reported
in apoptosis, cell-cycle arrest, proliferation, transformation and most recently
cell migration [8], [7], [16], [17]. However, only a few studies distinguish the
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contributions of jnk isoforms [140] probably because the commonly used mouse
embryonic fibroblast model lacks the expression of all the JNK isoforms [42].
Further the PyVMT model showed large variability in lung metastasis (Chap-
ter 3) and overall was not a very efficient model for metastasis studies. Thus,
subsequent studies focussed on JNK1, which is known to promote apoptosis,
using the robustly metastatic 4T1.2 cells.
The advantage of the 4T1.2 mammary carcinoma model is its close
resemblance to the actual human disease in terms of reliable development of
mammary tumors at the orthotopic site, the essential steps of tumor pro-
gression, and the high incidence of metastasis to the lung and bone [135].
Further, this model can be used to manipulate both the tumor cell and the
host microenvironment in order to study intrinsic and extrinsic effects of JNK1
signaling in mammary tumorigenesis.
To study the orl eof JNK1, retroviral delivery of shRNA was done
using a highly potent VSV-G (Vesicular Somatitis Virus Glycoprotein) which
delivers viruses via fusion with the host’s cell membrane. Using his method
we created stable JNK1 knockdown clones (Fig. 4.1A-C). Other JNK isoforms
namely JNK2 were not affected by JNK1 knockdown, allowing us to study the
independent effects of JNK1 (Fig. 4.1D).
The ability of tumor cells to degrade ECM components of the base-
ment membrane and surrounding tissues is directly correlated to its metastatic
potential. JNK1 is closely associated with stress response and activation of
c-Jun related cell cycle progression [198]. However, there are very few re-
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ports of JNK1 mediated proteolytic cell invasion. In vitro characterization of
the non-silencing vector and shJNK1 expressing vectors showed no significant
difference in proliferation, although cell invasion through MatrigelTM was in-
creased by two fold in the shJNK1 group (Fig4.2A). The principal classes of
enzymes that degrade the ECM-cell associations include proteases belonging
to the MMP family. JNK1, by virtue of its effects on transcriptional activity
of AP-1, regulates MMP9 expression [199], [3]. Also, by acting downstream of
MKK4, a known metastasis suppressor, JNK1 may inhibit malignancy [238].
Most importantly, the in vitro and in vivo roles for JNK1 can be very differ-
ent, as reported by another study [42]. Variability in arises from the effect of
extrinsic factors that influences how the cancer interprets JNK1 activation.
Injecting shJNK1 and non silencing (Scr) clones of 4T1.2 cells into the
4th mammary fat pad of syngeneic Balb/c mice produced orthotopic mam-
mary tumors at the site of injection within the reported time frame [135]. Al-
though both groups of mice had palpable tumors at the same time, the mean
tumor growth from the time of palpation until target volume was reached,
was significantly higher in case of 4T1.2shJNK1 cells compared to Scr tumor
growth(Fig 4.3A,B). Reciprocally the Scr tumor bearing mice had significantly
longer survival. When we analyzed the lung metastasis arising spontaneously
from the primary tumor, we noted a distinct trend of increased metastasis in
the shJNK1 group, although it did not reach statistical significance (p=0.2)
(Fig 4.3C). One possibility of this outcome is the difference in metastasis due
to loss of jnk1 is a late event, which is not detectable in this protocol due
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to the staggered time course of this experiment. Therefore, we opted for an
additional experimental metastasis study.
Intravenous injection of tumor cells via the lateral tail vein provides an
excellent opportunity to study the later stages of metastasis because cells are
directly inoculated into the circulation, forgoing dissemination and intrava-
sation processes [135]. Often called experimental metastasis, this approach
allows tracking of the rate of lung metastasis, since the mice are harvested at
the same time. Lungs are perfused with India ink to visualize the lung lobes
and visualize the metastases as white nodules against the dark lung tissue.
In this model shJNK1 injected animals formed significantly greater and larger
metastases than the non-silencing vector controls (Fig4.4A,B). This suggested
that the shJNK1 tumor possessed greater homing and colonization capabili-
ties.
Since JNK1 regulates transcription factors like AP-1, reduced expres-
sion of JNK1 alters gene expression [17]. Further, the effect of JNK1 knock-
down is more pronounced on cell survival, proliferation and invasion in vivo
than in vitro. Since the microenvironment can reversibly alter the phenotype
of tumor cells [13], identifying JNK1 targets in the tumors instead of the cell
lines would optimally incorporate the effects of tumor microenvironment.
Therefore, we performed a microarray-based analysis of the genetic
alteration in the 4T1.2shJNK1 and corresponding 4T1.2 Scr tumors to identify
novel targets of JNK1.
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My specific interest was in CCR5 is due to its emerging role in inflam-
matory response in cancer progression [224]. In an preliminary experiment,
the microarray result was verified using immunoblotting with CCR5 specific
antibody (Fig 4.6A). shJNK1 tumors showed a higher endogenous CCR5 ex-
pression.
Mesenchymal stem cells integrate and localize inside the breast carci-
noma associated stroma [15]. A recent publication by Weinberg’s group [120],
utilizing a tumor cell-mesenchymal stem cell, co-culture system, showed that
upregulation of CCL5 and CCR5 in mammary tumor cells induces concomi-
tant increase in ligand CCL5 both in vitro and in vivo. In vivo, tumor cells can
recruit MSCs from bone marrow that secrete chemokines and cytokines, much
like during wound healing [107]. The authors provided compelling evidence
that such tumor-stromal (CCR5-CCL5) paracrine loop upregulates mitogenic
signaling pathways in the tumor cells, detected as an increase in pAkt lev-
els. These interactions lead to a more aggressive phenotype in the tumor cells
[119].
In an early study we also observed similar upregulation of Akt activity
in the shJNK1 tumor and cell lines (Fig 4.6C) which encouraged us to pursue
CCR5 a target for JNK1. Loss of JNK1 transcriptionally increases CCR5 levels
in the tumor cells. When these cells are injected in vivo, they interact with the
mesenchymal cells of the mammary microenvironment. Due to proximity of
the tumor cell and the mesenchymal cell, the CCR5 receptor upregulates the
ligand expressed on the mesenchymal cell. This a local CCR5-CCL5 circuitry
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influences survival signaling in the tumor cell itself. A measure of which can
be upregulation of pAkt. This hypothetical pathway can lead to increased
tumorigenesis and metastasis in the shJNK1 group.
However, intense work is necessary to validate this hypothesis. Cur-
rently our ongoing research is aimed at resolving the role of CCR5 in promot-
ing metastasis in absence of JNK1 by using CCR5 knock downs as well as
4T1.2 tumor cell and mesenchymal cell co-cultures.
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Chapter 5
Conclusions and Future Directions
Overall my projects clearly demonstrated that JNK1 and JNK2 have
opposing roles in mammary tumor metastasis, in spite of their close structural
homology. We found that JNK2 increases directed cell migration in the murine
PyVMT mammary tumor model. Secondly, a small molecule JNK inhibitor
peptide, TAT-TI-JIP efficiently inhibited cell migration without causing exten-
sive cellular toxicity. Our most novel observation was the inverse association of
EPS8 with JNK2 in cancer and normal tissue. To our knowledge this is the first
instance where EPS8 expression is shown to be regulated by JNK2. However,
the functional outcome of systemic loss of JNK2 with higher levels of cellular
EPS8 was quite baffling, at least in terms of cell migration. EPS8 knockdown
in absence of endogenous JNK2 expression, increased migration potential of
PyVMTjnk2-/-tumor cells. Absence of JNK2 increased stability of EPS8 pro-
tein, which we suspected was due to impaired enodosomal-lysosomal trafficking
of EPS8. Further, inefficient internalization of growth factor ligand, EGF in
cells lacking JNK2 supported deregulation of endocytosis. It may be recalled
that EPS8 has dual functions in EGFR signaling and trafficking based on its
engagement with either Abi1 or RN-Tre via its SH3 domain. The signaling
module to which EPS8 will preferentially bind is possibly determined by an
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intracellular balance between EPS8 levels and its scaffold Abi1 and RN-Tre.
Accordingly, we found RN-Tre over expression in JNK2 expressing cells inhib-
ited wound healing. Lastly, in absence of JNK2, we failed to observe membrane
ruffles and EPS8 localization during early lamellipodia formation. These data
implied that JNK2 is essential for EPS8-SOS1-Abi1 complex formation. This
complex transduces signals from activated Ras and Rac, and leads to actin
reorganization for lamellipodia or membrane ruffle formation. Finally, lack of
correct actin remodeling due to improper spatiotemporal trafficking of EPS8
may lead to reduced cell migration in the tumor cells lacking JNK2. When
we looked at cell invasion, presence of JNK2 increased cell invasion only under
acidic matrix conditions. In vivo, the loss of JNK2 did not significantly pro-
tect animals against lung metastasis suggesting that the role of JNK2 in the
PyVMT model may not be very critical in metastasis. However, this might not
be an universal phenomenon and just a characteristic of the PyVMT model
itself since other members in the lab have found a correlation between JNK2
expression and increased metastasis.
Future studies will involve understanding the transcriptional control of
EPS8 by JNK2. Preliminary database searches revealed AP1 binding sites
on the EPS8 promoter region. Using ChIP assay we will determine if JNK2
regulates EPS8 transcription. Next, we will study EPS8 trafficking in greater
detail by overexpressing various endosomal compartment proteins and detect
co-localization of EPS8. We also propose to inhibit clathrin mediated en-
docytosis by expression of dominant-negative dynamins in wild type cells to
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correlate the role of endocytosis in mediating JNK2 dependent migration. One
of the drawbacks of this project was that we could not co-immunoprecipitate
endogenous EPS8 or any of its binding partners with JNK2. However, the ma-
jority of the studies on EPS8 and its binding interactions were done by using
ectopic overexpression of EPS8 or its binding partners. We are currently work-
ing on optimizing these co-immunoprecipitation studies and may used com-
mercially available crosslinkers for better binding assays. Lastly, since EPS8
is implicated in enhancing mitogenic response, we will create EPS8 knock-
down clones in 4T1.2 mammary carcinoma cells and orthotopically inject the
cells into mice to determine effects of EPS8 on primary tumor growth and
metastasis.
In contrast to the reduction in cell migration with loss of JNK2, we
found JNK1 deficiency increased tumor cell invasion and metastasis. Primary
tumor growth was greatly increased by reduced JNK1 levels in a 4T1.2 sponta-
neous tumorigenesis model. Significantly higher lung metastasis was observed
in the 4T1.2shJNK1 groups only upon intravenous injection of tumor cell via
lateral vein suggesting that JNK1 affects later stages of metastasis. Microar-
ray analysis of gene expression profiles in the primary tumors showed over 2
fold increase in CCR5 in the shJNK1 tumors. The first target we validated
at the protein level was CCR5, which is known be important for homing of
tumor cells to secondary metastatic sites. Tumor CCR5 can induce secretion
of CCL5 from proximal mesenchymal cells. Paracrine effects of CCL-5 include
upregulation of survival signaling, like activation of Akt in the primary tu-
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mor. Encouraging preliminary results revealed an increase in pAkt expression
in the 4T1.2shJNK1 primary tumors which may explain the increased growth
and metastasis of the 4T1.2shJNK1 tumors.
Future studies will address the role of mesenchymal stem cells in induc-
ing primary tumor growth in a JNK1 and CCR5 dependent manner. To this
end, we are currently in the process of extracting a populations of MSCs (mes-
enchymal stem cells) from the bone marrow of wild type mice to co-culture
them with 4T1.2shJNK1 clones. We will also manipulate the CCR5 expres-
sion in the tumor cells using shRNAs. Experimentation will involve in vitro
invasion assays, proliferation assay with mesenchymal-tumor cell co-cultures.
Finally, we will inoculate Balb/c mice with CCR5 knockdowns and study the
course of tumor development and metastasis.
Metastasis is the last frontier in cancer research. Even today managing
metastasis clinically is an enormous challenge. Preclinical research pursued in
our laboratory using both in vitro and in vivo models will facilitate the identi-
fication of rate limiting steps of metastasis cascade and model their molecular
mechanisms. Clinically such information can be utilized to develop novel ther-
apeutic strategies and more accurate risk stratification programs. Moreover
studying a kinase like JNK with multiple isoforms, highlights the nuances of
isoform specificity. One should not underestimate the outcome of using pan
JNK inhibitors since this research clearly shows the great functional diversity
of the JNK isoforms and their net effect in promoting metastasis.
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